

METHOD, COMPOSITIONS AND KIT FOR DETECTION OF MICROORGANISMS AND  
BI-DIRECTIONAL SEQUENCING OF NUCLEIC ACID POLYMERS

5  
A  
5  
SUB  
This application is a continuation-in-part of pending US Patent Applications Nos. 09/009,483 filed January 20, 1998, 08/640,672 filed May 1, 1996, now US Patent No. 5,789,168, 08/684,498 filed July 19, 1996, now US Patent No. 5,830,657, and 08/807,138 filed February 27, 1997, now US Patent No. 5,888,736, and of International Patent Application No. PCT/US97/07134 filed April 29, 1997 designating the United States, and published as International Publication No. WO 97/41259 on November 6, 1997, all of which are incorporated herein by reference.

BACKGROUND OF THE INVENTION

This application relates to a method for detection and identification of microorganisms, including in particular pathogenic microorganisms, and to compositions and kits useful in practicing the method. The invention can be applied to detection of viruses, including HIV and hepatitis, bacteria, including *Chlamydia*, fungi, including *Cryptococcus neoformans* and protozoa, including *Trypanosoma cruzi*. This application also relates to DNA sequencing reactions, and in particular to improved bi-directional sequencing reaction protocols making use of thermally stable polymerase enzymes.

Detection of the presence of pathogenic microorganisms through DNA-based technology is emerging as an important tool in the diagnosis of many diseases. For example, diagnosis of *Chlamydia trachomatis* infections, the most common bacterial sexually transmitted disease in North America, is shifting from traditional methods such as culture, enzyme immunoassay (EIA) and direct fluorescent antibodies (DFA) to DNA-hybridization diagnostics. Roche Diagnostic Systems, Inc. (Nutley, NJ) manufactures Amplicor™, a test which detects *C. trachomatis* and *Neisseria gonorrhoeae* by the hybridization of a pathogen specific probe to PCR amplified products, detectable by a color

change/optical density technique. Abbott Laboratories (Abbott Park, IL) makes UriProbe, also a test for *C. trachomatis* and *N. gonorrhoeae*, which relies on the ligase chain reaction (LCR). The LCR method, described in Patent Applications WO 9320227, WO 9300447, WO 9408047, WO 9403636, EP 477 972 uses thermostable ligase enzyme to ligate two DNA probes which hybridize in ligatable juxtaposition on a template DNA strand, thus generating a detectable ligated DNA fragment only if the template DNA is present. A multiplex PCR assay for *C. trachomatis* has also been described in Mahony et al., *J. Clin. Microbiol.* 33: 3049-3053 (1995).

The ideal DNA sequencing procedure for use in a diagnostic environment would have the following characteristics: (1) it would be able to utilize a DNA-containing sample which had been subjected to only minimal pretreatment to make the DNA accessible for sequencing; (2) it would require combining this sample with only a single reaction mixture, thus reducing risk of error and contamination, and increasing the ease with which the procedure can be automated; and (3) it would require a short amount of time to perform the sequence determination, thus decreasing the marginal costs in terms of equipment and labor for performing the test.

A wide variety of infectious pathogens that can be detected by DNA-based methods are listed in *Diagnostic Molecular Microbiology*, Persing et al., eds. American Society for Microbiology, Washington D.C. (1993). This text details diagnostic tests for bacteria, virus, fungi, and protozoa. Diagnostic tests are also proposed for identifying the presence of drug resistance genes or toxin genes.

Although these tests are generally effective for identifying an infectious disease-causing organism if present, they do not routinely provide information concerning the specific serotype, variant or form of the infecting organism. Depending on the organism in question, this information can be significant in determining the likely course of the infection, for determining the most appropriate therapeutic approach and for epidemiological purposes. Furthermore, the previously known assays involve several steps and are therefore more

susceptible to systematic error than would be a test with fewer steps. Thus, there remains a need for a simple test format which is generally applicable to the detection of microorganisms, including infectious disease-causing microorganisms, and particularly for a simple test which provides an indication of the specific nature, e.g., the serotype, of the organism. It is an object of the present invention to provide such a test.

It is an object of the present invention to provide reagent combinations useful in performing tests for infectious disease-causing microorganisms, including *Chlamydia* human papilloma virus(HPV) and HIV.

It is a further object of the present invention to provide kits useful in performing tests for infectious disease-causing microorganisms, including *Chlamydia*, HPV and HIV.

It is an additional object of the present invention to provide an improved method for bi-directional sequencing of DNA samples which is well-suited for use in the diagnostic environment and for automation.

It is an additional object of the invention to provide a method for bi-directional sequencing of DNA which utilizes a DNA-containing sample which has been subjected to only minimal pretreatment to make the DNA accessible for sequencing.

It is still a further object of the invention to provide a method for bi-directional sequencing of DNA which requires combining a complex DNA-containing sample with only a single reaction mixture, thus reducing risk of error and contamination, and increasing the ease with which the procedure can be automated.

### SUMMARY OF THE INVENTION

The present invention provides a method for the evaluation of a sample for the presence of a target microorganism which can be performed directly on a natural abundance DNA preparation obtained from the sample in a single reaction vessel. The method of the invention comprises the steps of:

5 (a) combining the natural abundance DNA preparation with first and second primers, a nucleotide triphosphate feedstock mixture, a chain-terminating nucleotide triphosphate and a thermally stable polymerase enzyme which incorporates dideoxynucleotides into an extending nucleic acid polymer at a rate which is no less than 0.4 times the rate of incorporation of deoxynucleotides to form a reaction mixture, said first and second primers binding to the sense and antisense strands of the DNA of the target microorganism, respectively, and flanking a selected region within the genome of the target microorganism;

10 (b) exposing the reaction mixture to a plurality of temperature cycles each of which includes at least a high temperature denaturation phase and a lower temperature extension phase, thereby producing a plurality of species of terminated fragments if DNA from the target microorganism is present in the sample, each species of terminated fragment corresponding to a different incorporation position for the chain-terminating nucleotide triphosphate in the DNA of the target microorganism; and

15 (c) evaluating the terminated fragments produced to determine the incorporation positions of the chain-terminating nucleotide triphosphate. Based on the incorporation positions, not only the presence but also the specific nature, e.g. the serotype, of any target microorganism present can be determined.

20 The present invention also provides a composition comprising a mixture of four deoxynucleotide triphosphates and at least one dideoxynucleotide triphosphate corresponding to one of the four deoxynucleotide triphosphates, wherein the dideoxynucleotide triphosphate is present in a mole ratio to the corresponding deoxynucleotide triphosphate of from 1:50 to 1:500, said composition further comprising a thermally stable polymerase enzyme which incorporates dideoxynucleotides into an extending  
25 nucleic acid polymer at a rate which is no less than 0.4 times the rate of incorporation of deoxynucleotides.

Also provided is a kit for detection of a target microorganism comprising, in packaged combination, the above composition and a pair of primers which bind to the sense and antisense strands, respectively, and flank a selected region within the genome target microorganism.

5           The present invention also provides a method for bi-directional sequencing a region of interest in a DNA sample. The method can be carried out using a single set of reagents which is added to a minimally-treated sample to produce useful sequencing results.

#### DETAILED DESCRIPTION OF THE INVENTION

10           The compositions and kits of the present invention can be employed in a bi-directional DNA sequencing method in many contexts including: (1) detection of mutations, particularly mutations of medical significance, in samples derived from a human patient, animal, plant or microorganism; (2) determination of HLA type ancillary to transplant procedures; (3) detection and identification of microorganisms, particularly pathogenic microorganisms, in a sample; and (4) in-situ sequencing reactions to produce sequencing fragments within a histological specimen which are then removed from a selected location on the tissue preparation and loaded onto a gel for sequence analysis. This latter approach is particularly useful for evaluation of archived samples in retrospective studies where the outcome of a disease condition is known, but the potentially causative mutation is not. This method can be used  
15           with labeled primers for single base sequencing (or multiple-base sequencing using multiple tissue samples).

20           In the context of detecting and identifying microorganisms, the invention provides a novel approach to the evaluation of a sample for the presence of a target microorganism and for the identification of the specific nature of any organism found to be present. The target  
25           microorganism may be virus, bacteria, fungi or protozoa. Specific non-limiting examples of microorganisms to which the invention can be suitably applied include bacteria such as *Mycobacteria tuberculosis*, *Rickettsia rickettsii*, *Ehrlichia chaffeensis*, *Borrelia burgdorferi*,

*Yersinia pestis*, *Treponema pallidum*, *Chlamydia trachomatis*, *Chlamydia pneumoniae*,  
*Mycoplasma pneumoniae*, *Mycoplasma sp.*, *Legionella pneumophila*, *Legionella dumoffii*,  
*Mycoplasma fermentans*, *Ehrlichia sp.*, *Haemophilus influenzae*, *Neisseria meningitidis*,  
*Streptococcus pneumoniae*, *S. agalactiae*, and *Listeria monocytogenes*; viruses such as  
Human Immunodeficiency Virus Type 1 (HIV-1), Human T-Cell Lymphotropic Virus Type 1  
(HTLV-1), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Herpes Simplex, Herpesvirus 6,  
Herpesvirus 7, Epstein-Barr Virus, Cytomegalovirus, Varicella-Zoster Virus, JC Virus,  
Parvovirus B19, Influenza A, B and C, Rotavirus, Human Adenovirus, Rubella Virus, Human  
Enteroviruses, Genital Human Papillomavirus (HPV), and Hantavirus; fungi such as  
*Cryptococcus neoformans*, *Pneumocystis carinii*, *Histoplasma capsulatum*, *Blastomyces*  
*dermatitidis*, *Coccidioides immitis*, and *Trichophyton rubrum*; and protozoa such as  
*Trypanosoma cruzi*, *Leishmania sp.*, *Plasmodium*, *Entamoeba histolytica*, *Babesia microti*,  
*Giardia lamblia*, *Cyclospora sp.* and *Eimeria sp.* The method of the invention may also be  
used for *Cryptosporidium* oocyst detection; for identification of bacterial toxin genes, such as  
the toxin genes from *Vibrio cholerae* 01, enterotoxigenic *Escherichia coli*, *Shigella sp.*,  
enteroinvasive *E. coli*, *Helicobacter pylori* (formerly *Campylobacter pylori*), toxigenic  
*Clostridium difficile*, *Staphylococcus aureus*, and *Streptococcus pyogenes* exotoxins; and  
for identification of anti-microbial resistance loci such as rifampin resistance mutations in  
*Mycobacterium tuberculosis* and *M. leprae*; HIV Drug Resistance, *erm* Erythromycin  
Resistance Genes, methicillin--resistance genes in *Staphylococcus*, Penicillinase-Producing  
genes in *Neisseria gonorrhoeae*, genes encoding aminoglycoside-modifying enzymes,  
genes encoding an extended spectrum of Beta-Lactamases, fluoroquinolone and isoniazid  
resistance mutations in *Mycobacterium tuberculosis*, and genes encoding  
vancomycin resistance in Enterococci.

The method of detecting and identifying the presence of a target microorganism may  
utilize bi-directional DNA sequencing, in which a natural abundance DNA-containing sample

10  
15  
20  
25  
suspected to contain the target microorganism is combined in a reaction mixture with (1) first and second primers that hybridize with the sense and antisense strands of the DNA of the target microorganism, respectively, and flank a selected region within the genome of the target microorganism, (2) a nucleotide triphosphate feedstock mixture, (3) at least one chain-terminating nucleotide triphosphate and (4) a polymerase enzyme which incorporates dideoxynucleotides into an extending nucleic acid polymer at a rate which is no less than 0.4 times the rate of incorporation of deoxynucleotides to form a reaction mixture. This reaction mixture is processed through a plurality of thermal cycles. Each thermal cycle includes at least an extension step which is performed at a temperature of around 68 to 75 °C and a denaturation step performed at a temperature of around 90 to 98 °C. In addition, the thermal cycles may include a separate annealing step performed at a temperature of 50 to 70 °C.

During each cycle, the primers each anneal to the respective strand of any target DNA present in the sample, and primer chain extension using the polymerase enzymes and the nucleotide triphosphate feedstocks proceeds until terminated by incorporation of a chain-terminating nucleotide triphosphate. This results in the production of sequencing fragments comparable to those generated in a conventional sequencing reaction. Analysis of these fragments provides information concerning the sequence of the selected region of the target DNA, and thus of the serotype of the target microorganism. Those extension products which are not terminated prior to reaching the region complementary to the other primer can serve as template for generation of sequencing fragments in later cycles, although this generally occurs to a very small extent. This method also provides for simultaneously determining the positions of a selected nucleotide base in a target region of both strands of a denatured duplex nucleic acid polymer. The method of the invention differs from the prior art, because the first and second oligonucleotide primers are each labeled with different, spectroscopically-distinguishable fluorescent labels. The method therefore obtains information about both DNA strands simultaneously while providing improved sensitivity as a

result of the non-linear increase in the amount of DNA which results from the production of additional templates molecules from unterminated fragments.

Among the advantages of the present invention is the ability to perform an evaluation directly on a "natural abundance" DNA sample. The nature of the initial sample will depend on the nature of the target microorganism. For example, in the case of *Chlamydia*, the initial sample employed in the present invention is suitably a urine sample, genital scraping or genital swab taken from a human patient, although other samples which are suspected of containing *Chlamydia* can also be tested using the method of the invention. Similarly, to test for HIV infection, the preferred sample is a blood sample.

As used herein a "natural abundance sample" is a sample which has been treated to make DNA in the sample accessible for hybridization with oligonucleotide primers, for example by lysis, centrifugation to remove cellular debris and proteolytic digestion to expose the DNA, but which has not been subjected to a preferential purification or amplification step to increase the amount of target DNA relative to non-target DNA present in the initial sample. The term "natural abundance" does not, however, require the presence of all the DNA from the original sample. Thus, a complex sample containing just nuclear DNA, or just mitochondrial DNA or some subfraction of nuclear or mitochondrial DNA obtained by isolation from a tissue sample but not subjected to preferential amplification would be a "natural abundance" sample within the meaning of that term in the specification and claims of this application. The term "natural abundance" would also include a DNA sample prepared by conversion, for example by reverse transcription, of a total mRNA preparation or the genome of an RNA virus to cDNA; DNA isolated from an individual bacterial colony growing on a plate or from an enriched bacterial culture; and a viral DNA preparation where substantially the entire viral genome is isolated. The term "natural abundance" does not encompass a sample in which the isolated DNA is not a complex combination of DNA molecules, and thus would not encompass, for example, a purified plasmid preparation containing only a single species of plasmid.



Natural abundance samples of mammalian DNA can be prepared from fluid samples, e.g., blood or urine or tissue samples by any of a number of techniques, including lysis, centrifugation to remove cellular debris and proteolytic digestion to expose the DNA; salt precipitation or standard SDS-proteinase K-phenol extraction. Natural abundance samples  
5 can also be prepared using kits, for example the Gentra PURE GENE DNA Isolation Kit.

Primers used in the method of the present invention can be any pair of primers which hybridize with the sense and antisense strands DNA of the target microorganism flanking a selected region of diagnostic relevance, and which do not both hybridize to neighboring locations in human DNA or other microbial DNA potentially found in the sample. As used  
10 herein, the term "flanking" will be understood to mean the positioning of primers at the 5'-ends of the selected region on each DNA strand, such that extension of the primers leads to replication of the region between the primers. The primers are preferably selected such that the primer pair flanks a region that is about 500 bp or less, although primers spanning larger regions of DNA can be utilized with adjustments to the sequencing mixture (generally an  
15 increase in the relative amount of deoxynucleotide triphosphates) to increase the amount of longer sequencing fragments produced.

Primers can be selected to hybridize with highly conserved regions which are the same in all variants of the target microorganism or can be prepared as degenerate primers to take known sequence variations at the primer site into account. Thus, the first and second  
20 primers of the invention may each be a discrete oligonucleotide species, or may be a set of oligonucleotide primers with similar but not identical sequences. Primers can also be selected to bind to the sense and antisense strands of DNA flanking a region of the genome of the target microorganism which is constant across all known variants and forms of the microorganism, in which case the method of the invention would provide detection but not any  
25 specific qualitative characterization of the microorganisms, i.e., such primers could not provide discrimination between subspecies, serovars, strains, sub-types, biovars, variants, serotypes or between closely related species of the target microorganism. An example of

such a primer pair is a primer pair that binds to the cryptic plasmid of *C. trachomatis* which is recognized as a suitably specific target sequence or detection purposes, but which is not known to vary from strain to strain. Preferably, however, the primers employed will flank a region of the target genome which is variable in sequence depending on the serotype of the organism. Thus, for *C. trachomatis* primers which flank portions of the omp1 gene are preferred. Similarly, in the case of HIV detection, primers flanking known mutation sites in the HIV protease gene or reverse transcriptase gene produce fragments which permit both detection of HIV and the identification of the HIV variant present in the sample. Primers MY09 and MY11 (See example 10) give sequence information for most relevant types of human papilloma virus (HPV) but not other viruses.

In an alternative embodiment, primer pairs are selected which, when treated under the conditions of the invention, give sequence information from a much wider variety of organisms. This is the case with eubacterial "universal" primers such as 91E and 13B listed in Appendix I which can be used to obtain sequence data from the 16S rDNA gene of many bacteria. These primers are useful for identifying which bacterium is present in a septic blood culture, or any other pure but unknown culture. Patient samples which contain a broad range of bacteria will give a complex result, consisting of many overlapping sequences when tested with these primers. The complex result may, in some cases, provide useful information about the bacteria present. However, in the normal course, it is advantageous to separate out the species, i.e. by plating them out first. In this case, individual pure colonies can be selected and identified.

In still another embodiment, the primer pairs are selected to determine whether a specific gene is present in the patient sample. The gene can be a toxin gene, a virulence gene, an anti-biotic resistance gene or a specific mutation which confers drug resistance or the like. Such a test can determine if a micro-organism is present and if it carries the gene at the same time.

Primers for other microorganisms can be derived from known sequence information. Appendix I lists a collection of suitable primer pairs for various other microorganisms which are taken from Persing et al., *supra*.

One or both of the primers may be labeled with a detectable label at the 5'-end thereof, particularly a fluorescent label such as fluorescein or a cyanine dye such as Cy 5.5. If labels are used on both primers, the labels selected should be spectroscopically-distinct, i.e., they should have either a different excitation spectrum or a different emission spectrum such that one primer can be distinguished from the other. When both primers are labeled with different detectable labels, the sequence of both strands of the sample can be determined in a single reaction.

The nucleotide triphosphate feedstock mixture is a standard mixture of the four conventional bases (A, C, G and T) in a buffer suitable for template-dependent primer extension with the enzyme employed. As will be appreciated by persons skilled in the art, the specific concentrations of the nucleotide triphosphates and the nature of the buffer will vary depending on the enzyme employed. Standard buffers and reagent concentrations for various known polymerase enzymes may be employed in the invention.

The reaction mixture used in the present invention also includes at least one type of chain-terminating nucleotide triphosphate. Separate reactions for the four different types of bases may be run either concurrently or successively. Running all four bases concurrently comports with conventional sequencing practice. However, a preferred embodiment of the present invention combines the single vessel methodology of this application with "single track sequencing" which is described in commonly assigned US Patent No. 5,835,189. In single track sequencing, the determination of the positions of only one (or in any event less than 4) nucleotide(s) of a target sequence is frequently sufficient to establish the presence of and determine the qualitative nature of a target microorganism by providing a finger-print or bar-code of the target sequence that may be sufficient to distinguish it from all other known varieties of the sequence. Throughput is increased by reducing the number of reactions and

electrophoresis runs required to identify a sequence. By selection of the order of bases tested, and intermediate analysis, it may be unnecessary to run all four bases to determine the presence and specific qualitative nature of any target microorganism present in the sample.

5       The polymerase enzyme used in the invention is a thermostable polymerase enzyme which incorporates dideoxynucleotides into an extending nucleic acid polymer at a rate which is no less than 0.4 times the rate of incorporation of deoxynucleotides. ThermoSequenase™ is exemplary of such an enzyme. Reeve et al., *Nature* 376: 796-797 (1995). Tabor et al. have also described enzymes which have increased processivity and increased levels of  
10 incorporation of dideoxynucleotides. (See EP-A1-0 655 506, which is incorporated herein by reference) Roche sells an enzyme under the trademark TAQ-FS which meets these criteria as well.

15       The absolute and relative amounts of nucleotide triphosphates and chain-terminating nucleotide triphosphates may be optimized for the particular enzyme employed. In general, however, the nucleotide triphosphates will be included at in the reaction mixture at concentrations of from 250  $\mu$ M to 1.5 mM, and the chain-terminating nucleotide triphosphate will be included at a level of from 0.5  $\mu$ M to 30  $\mu$ M to produce compositions in which the mole ratio of the chain terminating nucleotide triphosphate to the corresponding nucleotide triphosphate is from 1:50 to 1:1000, preferably from 1:100 to 1:500. This will result in  
20 incorporation of a chain-terminating nucleotide triphosphate into from 30 to 100 percent of the extending polymer chains formed during the thermal cycling of the reaction mixture.

25       The method of the invention is suitably practiced using a kit which provides the appropriate reagents in conveniently packaged form. To reduce the number of sample preparation steps, and thus to reduce the risk of erroneous results, such a kit will suitably include at least one pre-prepared mixture comprising all four nucleotide triphosphates and at least one chain terminating nucleotide triphosphate, where the mole ratio of chain terminating

nucleotide to the corresponding deoxynucleotide triphosphate is from 1:50 to 1:1000, preferably 1:100 to 1:500.

The invention will now be further described by way of the following non-limiting examples.

#### EXAMPLE 1

The presence of the sexually transmitted disease pathogen *Chlamydia trachomatis* in a patient sample is detected according to the method of the invention as follows.

Urine samples from patients suspected of carrying a sexually transmitted disease pathogen are prepared for sequence-based diagnosis as follows. 100 ul of first void urine are deposited in a sterile microcentrifuge tube. The tube is centrifuged at 12,000 x g for 20 min; the supernatant is removed. 100 ul of Lysis Solution (Proteinase K @ 100 g/ml; 1% Tween 20) is added to the bacterial pellet and incubated 1 h at 55°C, or 18 h at room temperature. After a final incubation at 95°C for 10 minutes, 200 ul of GeneClean II glass milk is added, according to the manufacturer's instructions. (Bio 101, Inc) DNA is eluted in 10 ul of double distilled H<sub>2</sub>O. (A lysis solution control may be prepared if desired, by adding the lysis solution to a sterile tube (a tube without any urine pellet), and treating this tube like the others.)

The sample natural abundance DNA is then treated according to the method of the invention with a pair of primers and reagents to identify the sequence of a *C. trachomatis* gene present in the sample, if any. A suitable *C. trachomatis* specific target for sequencing is the cryptic plasmid. Primers that may be used are

<u>Name</u>	<u>Sequence</u>
-------------	-----------------

KL1:	TCCGGAGCGA GTTACGAAGA	[SEQ ID NO: 1]
------	-----------------------	----------------

KL2:	ATTCAATGCC CGGGATTGGT	[SEQ ID NO: 2]
------	-----------------------	----------------

These sequencing primers were employed previously for PCR amplification reactions, but not sequencing (Mahony et al., "Confirmatory polymerase chain reaction testing for

Chlamydia trachomatis in first void urine from asymptomatic and symptomatic men" *J. Clin Microbiol.* 30:2241-2245 (1992)).

Either primer may be labeled at the 5'-end with a detectable label such as a Cy5.5 fluorophore. If both primers are labeled, they should be distinguishable. Labels are selected on the basis of the instrument employed for detection. Labeling reactions are performed according to methods well known in the art, such as amidite labeling or dye-ester condensation.

The sequencing reaction mixture is prepared by combining 2.5 ul of the prepared DNA sample, 0.67 ul of 10 uM primer KL1 (labeled with Cy5.5), 0.45 ul of KL2 primer at 10 uM, 2 ul of THERMOSEQUENASE reaction buffer (250 mM Tris-HCl pH 9.0 @ 25°C, 39 mM MgCl<sub>2</sub>), 2 ul of THERMOSEQUENASE enzyme (Amersham Life Sciences) diluted 1/10 in the dilution buffer provided with the enzyme and 5.38 ul of double distilled H<sub>2</sub>O. The final volume is 13 ul.

3 ul of the sequencing reaction mixture is placed in each of 4 clean tubes and covered with one drop of mineral oil (Sigma Chemical Co., Cat # M-5904). The tube is placed in a PTC-100 thermal cycler (M.J. Research, Maine) and heated for 3 min at 94°C, then cooled to 85°C. One of the following termination mixtures are then added to each of the 4 tubes:

3 ul of dNTP:ddATP (1 mM each dNTP, 3.3 uM ddATP) in tube A.

3 ul of dNTP:ddCTP (1 mM each dNTP, 3.3 uM ddCTP) in tube C.

3 ul of dNTP:ddGTP (1 mM each dNTP, 3.3 uM ddGTP) in tube G.

3 ul of dNTP:ddTTP (1 mM each dNTP, 3.3 uM ddTTP) in tube T.

The dNTP:ddNTP mixes are preferably heated to 85°C when added to the tube. The reaction mixture is mixed well and it is subjected to the following thermal cycling regime for 55 cycles:

94°C/30 sec.

60°C/30 sec.

70°C/1 min.

After the last cycle, the tubes are kept at 70°C for 2 min, then cooled to 4°C until ready for loading. To view the reaction products, 6 ul of loading buffer (dye/stop solution) is added to each tube. The aqueous phase (the bottom phase disposed under the oil layer) is removed and put it in another tube. The sample is heated to 75°C for 3 min, and put on ice. 2 ul of each sample is loaded in each well of a MicroGene Blaster automated DNA sequencer (Visible Genetics Inc., Toronto, ON). The reaction products are electrophoretically separated and detected. The data is analyzed using GeneObjects software (Visible Genetics Inc., Toronto, ON) to base-call (i.e. determine the DNA sequence) of the samples. The base-called sequence is compared to the known *C. trachomatis* sequence to confirm diagnosis. Results are reported to the patient file.

#### EXAMPLE 2

The method of the invention may be employed to identify not only the presence of *C. trachomatis* in a patient sample but also the strain identity. Health care workers currently seek to distinguish among *Chlamydia trachomatis* strains to determine the molecular epidemiologic association of a range of diseases with infecting genotype (See Dean, D. et al "Major Outer Membrane Protein Variants of *Chlamydia trachomatis* Are Associated with Severe Upper Genital Tract Infections and Histopathology in San Francisco." J. Infect. Dis. 172:1013-22 (1995)).

A suitable strain specific target for *C. trachomatis* is the omp1 (outer membrane protein) gene which has at least 4 variable sequence ("VS") domains that may be used to distinguish among the 15 known genotypes of *C. trachomatis* (Yuan, Y et al. "Nucleotide and Deduced Amino Acid Sequences for the Four Variable Domains of the Major Outer Membrane Proteins of the 15 *Chlamydia trachomatis* Serovars" Infect. Immun. 57 1040-1049 (1989)).

Strain identification is achieved using the method of Example 1 with the following modifications. First of all, because of the length of the VS domains, separate reactions are

performed to obtain sequence from VS1/VS2 and VS3/VS4. The following oligonucleotide primers may be employed:

For VS1/VS2:

Name	Sequence	
MF21	CCGACCGCGT CTTGAAAACA GATGT	[SEQ. ID NO. 3]
MB22	CACCCACATT CCCAGAGAGC T	[SEQ. ID NO. 4]

For VS3/VS4

Name	Sequence	
MVF3	CGTGCAGCTT TGTGGGAATG T	[SEQ. ID NO. 5]
MB4	CTAGATTTC A TCTTGTTC A A TTGC	[SEQ. ID NO. 6]

These sequencing primers were employed previously for PCR amplification reactions, but not sequencing. Mahoney et al., *supra*.

These oligonucleotide primers are used in separate reactions in place of KL1 and KL2 in Example 1. The sample preparation and sequencing reactions are performed as in Example 1. The reaction products are electrophoretically separated and detected on a MicroGene Blaster automated DNA sequencing apparatus (Visible Genetics Inc., Toronto, ON). The data is analyzed using GeneObjects software to base-call the samples and to compare the data to the known varieties of *C. trachomatis*. Pure populations generally give unambiguous sequence data. Where heterozygous mixed populations are detected, a circumstance thought to occur in 1-3% of clinical *C. trachomatis* samples, the software identifies the strains which could be combined to result in the particular heterozygote sample detected.



EXAMPLE 3

Strain-specific *C. trachomatis* identification over the VS1/VS2 domain can be achieved according to the method in Example 1, by using the following degenerate primers sets:

Forward

OMP291: AGCATGCGTR TKGGTTACTA YGG [SEQ ID NO. 7]

(labeled with Cy5.5). Base 175 to 197 of the ORF of the omp1 gene of *C. trachomatis*.

Forward

OMP314A: TGACTTTGTT TTCGACCGYG TTTT [SEQ ID NO. 8]

(labeled with Cy5.5). Base 198 to 221 of the ORF of the omp1 gene of *C. trachomatis*.

Reverse

OMP722: CTAAAGTYGC RCATCCACAT TCC [SEQ ID NO. 9]

Base 637 to 615 of the ORF of the omp1 (in serovar K) gene of *C. trachomatis*. The primer may not have the EXACT SAME sequence as in serovar K.

Reverse

OMP711: CATCCACATT CCCASARAGC TGC [SEQ ID NO. 10]

Base 626 to 604 of the ORF of the omp1 (in serovar K) gene of *C. trachomatis*. The primer may not have the exact same sequence as in serovar K.

These primers sets are preferably used in the following combinations:

(1) OMP291-OMP722, sequencing a 455 to 463-bp (depending on the serotype) fragment of the omp1 gene of *C. trachomatis*; or

(2) OMP314A-OMP711, sequencing a 421 to 430-bp (depending on the serotype) fragment of the omp1 gene of *C. trachomatis*.

#### EXAMPLE 4

5 The method as exemplified in Examples 1, 2 and 3 may be further improved by employing different labels, preferably fluorescent labels, on the different primers for use in a multi-dye sequencer. This method takes advantage of the fact that a given termination mixture containing, for example, ddATP will give chain termination products for the A nucleotide in both directions. The different primer labels means that one reaction mixture loaded in a single lane of an automated DNA sequencing apparatus designed to detect the two labels (a "multi-dye sequencer") will identify the A nucleotide of both sense and antisense strands. Separate reactions are performed for the other 3 nucleotides. Using only 4 lanes of an electrophoresis gel, and 4 reaction mixtures, the DNA sequences of both the sense and anti-sense strands can be obtained. This information allows the operator to resolve any ambiguities that may be present.

10 Use of two different labels lends itself to a further improvement. As noted above, in a reaction according to the invention, the results of the ddATP reaction will give chain termination products for the A nucleotide in both directions. Since the A nucleotide in one direction corresponds to the T nucleotide in the other, a single reaction can provide the location of two bases. A second termination reaction with, for example, ddCTP will then obtain the positions of the other two nucleotides, C and G. Thus only two lanes of an electrophoresis gel and 2 reaction mixtures are required to identify the location of all 4 bases of the sequence.

15 A suitable multi-dye sequencer for use with this aspect of the invention, is the Applied Biosystems 377 Prism automated DNA sequencer (Applied Biosystems Inc., Foster City, CA). The fluorescent labels are selected to be detectable on the 377 instrument. Instead of the dye-terminator chemistry suggested in the Applied Biosystems product literature,

however, the fluorescent labels must be conjugated to the 5' end of the primer molecules. The samples are electrophoresed, detected and the detected data is recorded.

Sophisticated software such as GeneObjects software (Visible Genetics Inc, Toronto, CA) may be used to assist in evaluation of the results. This software may employ the methods of commonly assigned US Patent No. 5,853,979, US Patent Application No. 08/670,534 and International Patent Application No. PCT/US96/11130, published as WO97/02488, all of which are incorporated herein by reference. In one of the methods, the single nucleotide data tracks are evaluated and nucleotides are positioned relative to the known (or standard) DNA sequence expected from the sample. When data tracks are generated for each of the four nucleotides, the full DNA sequence of the sample may be base-called. The base-called sequence is then compared to the library of known sequences to determine which *C. trachomatis* strain or strains are present in the sample.

#### EXAMPLE 5

The sequence of both the sense strand and antisense strand of a *C. trachomatis* cryptic plasmid gene may be obtained in a one step reaction using the primers:

Name	Sequence	
KL1:	TCCGGAGCGA GTTACGAAGA	[SEQ ID NO. 1]
CT1590:	ATGCCCGGGA TTGGTTGATC	[SEQ ID NO. 11]

Combine the following materials and mix well:

	Concentration	Amount
Patient Sample DNA		11.25 ul
KL1*Cy5.5 Primer	10 uM	3 ul
CT1590*Fluoresceine Primer	10 uM	2 ul
Enzyme Diluent (Amersham plc)		8 ul
ThermoSequenase Enzyme	32 U/ul	0.9 ul

double distilled H<sub>2</sub>O

24.2 ul

Take 11 ul of the mixture and add 2 ul of 13X buffer [Tris-HCl 260 mM pH 8.3, MgCl<sub>2</sub> 39 mM] (final concentration 20 mM Tris-HCl pH 8.3, 3 mM MgCl<sub>2</sub>). Mix well and place 3 ul into each of 4 tubes. Heat tube to 94°C for 5 mins then reduce temperature to 85°C. Add and mix 3 ul of an 85 C dNTP/ddNTP solution consisting of 0.75 mM each dNTP and 2.5 uM of a chain terminating nucleotide triphosphate (ddNTP) (use a different ddNTP in each of the 4 tubes).

Treat the mixture to 60 cycles of the following thermal cycling reactions: 94°C for 10 sec, 62°C for 15 sec, 70°C for 1 min. Upon completion, treat the mixture for a final 5 min at 70 C and then store at 4°C until ready for loading. For viewing the reaction products, add an equal volume of stop/loading solution (95% formamide plus a colored dye). Take 1.5 ul and load in a single lane of a MicroGene Blaster automated DNA sequencer (Visible Genetics Inc., Toronto). Load the remaining mixture (@ 10.5 ul) in a single lane of an ALF Automated Sequencer (Pharmacia LKB, Uppsala, Sweden). The reaction products from the Cy5.5 labeled primer are detected on the MicroGene Blaster using GeneObjects Software. The reaction products from the fluorescein labeled primer are detected on the ALF Automated Sequencer using GeneObjects Software. The base-calling results of the Cy5.5 labeled primer were compared to the known sequence of the gene by the GeneLibrarian component of GeneObjects.

#### EXAMPLE 6

As described in U.S. Patent No. 5,834,189, not all 4 nucleotides of *C. trachomatis*, or any polymorphic or multiple allelic locus of any gene or organism necessarily need to be determined in order to ascertain which allele or variant is present. In many cases, positioning less than four nucleotides may be sufficient to determine with certainty which allele is present.

The method of Examples 1- 4 may be modified to obtain single nucleotide data tracks (or fragment patterns) by performing only one of the termination reactions at a time.

In the case of detection and serotyping of *C. trachomatis*, the evaluation of the A track alone over the first 100 nucleotides of the *omp1* gene, aligning to nucleotides 249-349 of the serovars C and K, can distinguish the serovars. Appendix II is a text file representation of the *omp1* gene in each of the serovars. The sequences are all aligned to the last (3') nucleotide of the detectably labeled primer omp314A. (Appendix II shows sequences starting 29 bp downstream of the 3'-nucleotide.) This illustration differs from a traditional "consensus" sequence illustrations in that all missing bases (usually represented by N's or raised dashes) are deleted. The A's are illustrated in the order and positions in which they would be expected to appear after a sequencing reaction and upon detection by an automated DNA electrophoresis apparatus.

If, in another microorganism, the A lane (or other preferred first lane) were not sufficient to distinguish all types, a second reaction for the C, G or T nucleotide could be performed to further define the qualitative nature of any target microorganism present in the sample. Because the sequences of the types are previously known, the operator can determine which of the nucleotides provide the greatest information and will analyze those nucleotides first.

#### EXAMPLE 7

The presence of and strain identity of *C. trachomatis* in a patient sample may be determined according to the methods of the previous examples by substituting the following primer pairs. These primers are used to determine the sequence of the *omp1* gene (publicly available at DNASIS Accession No. X62921).

Forward Primer (5' Primer) labeled with a detectable label such as Cy5.5:

Primer OMP312: GGAGACTTTG TTTTCGACCG

[SEQ ID NO 12]

Position 312-331 of X62921

and one of the following Reverse Primers (3' Primer) (optionally labeled with a detectable label different from the 5' primer):

Primer OMP708: CATTCCCACA AAGCTGCGCG [SEQ ID NO 13]

Position 727-708 of X62921

Primer OMP706: TTCCCACAAA GCTGCGCGAG [SEQ ID NO 14]

Position 725-706 of X62921

Primer OMP704: CCCACAAAGC TGCGCGAGCG [SEQ ID NO 15]

Position 723-704 of X62921

The following combination can be used to obtain DNA sequence over the following maximum lengths:

OMP312-OMP708: 416-nt region of omp1

OMP312-OMP706: 414-nt region of omp1

OMP312-OMP704: 412-nt region of omp1

#### EXAMPLE 8

The presence of and strain identity of *C. trachomatis* in a patient sample may be determined according to the method of previous examples, using *C. trachomatis* ribosomal DNA (rDNA) specific primers such as

CT220 ACCTTTCGGT TGAGGGAGAG TCTA [SEQ ID NO 16]

and

CT447 GGACCAATTC TTATTCCCAA GCGA [SEQ ID NO 17]

Haydock et al., Chap 1.10 in Persing et al., *supra*.

EXAMPLE 9

The sequence of both the sense strand and antisense strand of the protease gene of HIV-1 integrated into natural abundance DNA of lymphocytes may be obtained in a one step reaction as follows.

5 Natural abundance DNA is prepared from the patient blood lymphocyte sample according to a standard method such as a standard salting-out procedure (as provided by the Puregene DNA Isolation Kit, Gentra Systems, Inc., Minneapolis) or by detergent and proteinase K treatment (Current Protocols in Molecular Biology, Eds. Ausubel, F.M. et al, (John Wiley & Sons; 1995)).

10 Combine the following materials and mix well:

	Concentration	Amount
Patient Sample DNA		11.25 ul
PR211F*Cy5.5 Primer	10 uM	3 ul
or		
PR281*Cy5.5 Primer	10 uM	3 ul
PR526*Fluorescein Primer	10 uM	2 ul
Enzyme Diluent (Amersham plc)		8 ul
THERMOSEQUENASE Enzyme	32 U/ul	0.9 ul
double distilled H2O		24.2 ul

20 The primers have the following sequences:

Name	Sequence
------	----------

Choice of Forward Primers

PR211F	ATCACTCTTT GGCAACGACC	[SEQ ID No. 18]
--------	-----------------------	-----------------

(FORWARD), BASE 6 TO 25 OF THE PROTEASE GENE

or

PR281	CAGGAGCAGA TGATACAGTA TTAG	[SEQ ID No. 19]
-------	----------------------------	-----------------

(FORWARD), BASE 76 TO 99 OF THE PROTEASE GENE

Reverse Primer

PR526: CCATTCCTGG CTTTAATTTT ACTGG

[SEQ ID No. 20]

(REVERSE), BASES 321 TO 345 OF THE PROTEASE GENE

PR211F-PR526 creates a sequencing fragment of maximum size 340 bp.

PR281-PR526 creates a sequencing fragment of maximum size 270 bp. Both regions contain the sequence of the various codons where mutations are involved in protease inhibitor resistance (Codons 46, 48, 54, 63 82 84 and 90).

Take 11 ul of the mixture and add 2 ul of 13X buffer [Tris-HCl 260 mM pH 8.3, MgCl<sub>2</sub> 39 mM] (final concentration 20 mM Tris-HCl pH 8.3, 3 mM MgCl<sub>2</sub>). Mix well and place 3 ul into each of 4 tubes. Heat tube to 94 C for 5 mins then reduce temperature to 85 C. Add and mix 3 ul of an 85 C dNTP/ddNTP solution consisting of 0.75 mM each dNTP and 2.5 uM of a chain terminating nucleotide triphosphate (ddNTP) (use a different ddNTP in each of the 4 tubes).

Treat the mixture to 60 cycles of the following thermal cycling reactions: 94 C for 10 sec, 62 C for 15 sec, 70 C for 1 min. Upon completion, treat the mixture for a final 5 min at 70 C and then store at 4 C until ready for loading. For viewing the reaction products, add an equal volume of stop/loading solution (95% formamide plus a coloured dye). Take 1.5 ul and load in a single lane of a MicroGene Blaster automated DNA sequencer (Visible Genetics Inc., Toronto). Load the remaining mixture (@ 10.5 ul) in a single lane of an ALF Automated Sequencer (Pharmacia LKB, Uppsala, Sweden). The reaction products from the Cy5.5 labelled primer are detected on the MicroGene Blaster using GeneObjects Software. The reaction products from the fluorescein labeled primer are detected on the ALF Automated Sequencer using GeneObjects Software. The base-called results from each primer were compared to the known sequences of HIV-1 by GeneLibrarian (a component of GeneObjects (Visible Genetics Inc, Toronto).



EXAMPLE 10

The presence and type of human papilloma virus (HPV) present in a patient sample can be determined according to the method of the invention by following the protocol in Example 1 with the following modifications.

Patient sample DNA is extracted from 250 ul urine specimens using GeneClean II (Bio 101, Inc.). The sample is then treated as described previously but employing the degenerate primer pair:

Forward Primer: MY11

GCMCAGGGWC ATAAYAATGG [SEQ ID No. 21]

Reverse Primer: MY09

CGTCCMAARG GAWACTGATC [SEQ ID No. 22]

The reactions are performed as before, using ThermoSequenase enzyme or the like. Reaction products are detected on an automated electrophoresis/detection device such as the MicroGene Blaster. The sequence is analyzed and compared to the known varieties of HPV to identify the type. The result is reported to the patient file.

Although the preferred embodiments of the invention has been described above in some detail, it should be appreciated that a variety of embodiments will be readily apparent to one skilled in the art. The description of the invention is not intended to be limiting to this invention, but is merely illustrative of the preferred embodiments.

APPENDIX I

Suitable Sequencing Primer Pairs for Identification and Sub-Typing of Infectious Pathogens

cf. Diagnostic Molecular Microbiology (Eds. Persing et al.) (1993; American Society for  
Microbiology; Washington D.C.)

Bacterial Pathogens Universal (16S rDNA) Typing Primers

Pathogen Name: Universal Bacterial Identification

Gene: 16s rDNA

Forward Primer: 91E

TCAAAGGAAT TGACGGGGGC [SEQ ID No. 23]

Site of Specific Hybridization: nt 911-930

Reverse Primer:13B

AGGCCCGGGA ACGTATTCAC [SEQ ID No. 24]

Site of Specific Hybridization: nt 1390-1371

Maximum fragment size: 475 nt

Pathogen Name: Universal Bacterial Identification

Gene: 16s rDNA

Forward Primer: 515FPL

TGCCAGCAGC CGCGGTAA [SEQ ID No. 25]

Site of Specific Hybridization: nt 515-533

Reverse Primer:806R

GGACTACCAG GGTATCTAAT [SEQ ID No. 26]

Site of Specific Hybridization: nt 806-787

Maximum fragment size: 328 nt

Pathogen Name: Universal Bacterial Identification

Gene: 16s rDNA

Forward Primer: 11E

GAGGAAGGTG GGGATGACGT

[SEQ ID No. 27]

5 Site of Specific Hybridization: nt 1175-1194

Reverse Primer: 13B

AGGCCCGGGA ACGTATTAC

[SEQ ID No. 28]

Site of Specific Hybridization: nt 1390-1371

Maximum fragment size: 233 nt

10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1320  
1321  
1322  
1323  
1324  
1325  
1326  
1327  
1328  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336  
1337  
1338  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357  
1358  
1359  
1360  
1361  
1362  
1363  
1364  
1365  
1366  
1367  
1368  
1369  
1370  
1371  
1372  
1373  
1374  
1375  
1376  
1377  
1378  
1379  
1380  
1381  
1382  
1383  
1384  
1385  
1386  
1387  
1388  
1389  
1390  
1391  
1392  
1393  
1394  
1395  
1396  
1397  
1398  
1399  
1400  
1401  
1402  
1403  
1404  
1405  
1406  
1407  
1408  
1409  
1410  
1411  
1412  
1413  
1414  
1415  
1416  
1417  
1418  
1419  
1420  
1421  
1422  
1423  
1424  
1425  
1426  
1427  
1428  
1429  
1430  
1431  
1432  
1433  
1434  
1435  
1436  
1437  
1438  
1439  
1440  
1441  
1442  
1443  
1444  
1445  
1446  
1447  
1448  
1449  
1450  
1451  
1452  
1453  
1454  
1455  
1456  
1457  
1458  
1459  
1460  
1461  
1462  
1463  
1464  
1465  
1466  
1467  
1468  
1469  
1470  
1471  
1472  
1473  
1474  
1475  
1476  
1477  
1478  
1479  
1480  
1481  
1482  
1483  
1484  
1485  
1486  
1487  
1488  
1489  
1490  
1491  
1492  
1493  
1494  
1495  
1496  
1497  
1498  
1499  
1500  
1501  
1502  
1503  
1504  
1505  
1506  
1507  
1508  
1509  
1510  
1511  
1512  
1513  
1514  
1515  
1516  
1517  
1518  
1519  
1520  
1521  
1522  
1523  
1524  
1525  
1526  
1527  
1528  
1529  
1530  
1531  
1532  
1533  
1534  
1535  
1536  
1537  
1538  
1539  
1540  
1541  
1542  
1543  
1544  
1545  
1546  
1547  
1548  
1549  
1550  
1551  
1552  
1553  
1554  
1555  
1556  
1557  
1558  
1559  
1560  
1561  
1562  
1563  
1564  
1565  
1566  
1567  
1568  
1569  
1570  
1571  
1572  
1573  
1574  
1575  
1576  
1577  
1578  
1579  
1580  
1581  
1582  
1583  
1584  
1585  
1586  
1587  
1588  
1589  
1590  
1591  
1592  
1593  
1594  
1595  
1596  
1597  
1598  
1599  
1600  
1601  
1602  
1603  
1604  
1605  
1606  
1607  
1608  
1609  
1610  
1611  
1612  
1613  
1614  
1615  
1616  
1617  
1618  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1630  
1631  
1632  
1633  
1634  
1635  
1636  
1637  
1638  
1639  
1640  
1641  
1642  
1643  
1644  
1645  
1646  
1647  
1648  
1649  
1650  
1651  
1652  
1653  
1654  
1655  
1656  
1657  
1658  
1659  
1660  
1661  
1662  
1663  
1664  
1665  
1666  
1667  
1668  
1669  
1670  
1671  
1672  
1673  
1674  
1675  
1676  
1677  
1678  
1679  
1680  
1681  
1682  
1683  
1684  
1685  
1686  
1687  
1688  
1689  
1690  
1691  
1692  
1693  
1694  
1695  
1696  
1697  
1698  
1699  
1700  
1701  
1702  
1703  
1704  
1705  
1706  
1707  
1708  
1709  
1710  
1711  
1712  
1713  
1714  
1715  
1716  
1717  
1718  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1730  
1731  
1732  
1733  
1734  
1735  
1736  
1737  
1738  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748  
1749  
1750  
1751  
1752  
1753  
1754  
1755  
1756  
1757  
1758  
1759  
1760  
1761  
1762  
1763  
1764  
1765  
1766  
1767  
1768  
1769  
1770  
1771  
1772  
1773  
1774  
1775  
1776  
1777  
1778  
1779  
1780  
1781  
1782  
1783  
1784  
1785  
1786  
1787  
1788  
1789  
1790  
1791  
1792  
1793  
1794  
1795  
1796  
1797  
1798  
1799  
1800  
1801  
1802  
1803  
1804  
1805  
1806  
1807  
1808  
1809  
1810  
1811  
1812  
1813  
1814  
1815  
1816  
1817  
1818  
1819  
1820  
1821  
1822  
1823  
1824  
1825  
1826  
1827  
1828  
1829  
1830  
1831  
1832  
1833  
1834  
1835  
1836  
1837  
1838  
1839  
1840  
1841  
1842  
1843  
1844  
1845  
1846  
1847  
1848  
1849  
1850  
1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1860  
1861  
1862  
1863  
1864  
1865  
1866  
1867  
1868  
1869  
1870  
1871  
1872  
1873  
1874  
1875  
1876  
1877  
1878  
1879  
1880  
1881  
1882  
1883  
1884  
1885  
1886  
1887  
1888  
1889  
1890  
1891  
1892  
1893  
1894  
1895  
1896  
1897  
1898  
1899  
1900  
1901  
1902  
1903  
1904  
1905  
1906  
1907  
1908  
1909  
1910  
1911  
1912  
1913  
1914  
1915  
1916  
1917  
1918  
1919  
1920  
1921  
1922  
1923  
1924  
1925  
1926  
1927  
1928  
1929  
1930  
1931  
1932  
1933  
1934  
1935  
1936  
1937  
1938  
1939  
1940  
1941  
1942  
1943  
1944  
1945  
1946  
1947  
1948  
1949  
1950  
1951  
1952  
1953  
1954  
1955  
1956  
1957  
1958  
1959  
1960  
1961  
1962  
1963  
1964  
1965  
1966  
1967  
1968  
1969  
1970  
1971  
1972  
1973  
1974  
1975  
1976  
1977  
1978  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
1988  
1989  
1990  
1991  
1992  
1993  
1994  
1995  
1996  
1997  
1998  
1999  
2000  
2001  
2002  
2003  
2004  
2005  
2006  
2007  
2008  
2009  
2010  
2011  
2012  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020  
2021  
2022  
2023  
2024  
2025  
2026  
2027  
2028  
2029  
2030  
2031  
2032  
2033  
2034  
2035  
2036  
2037  
2038  
2039  
2040  
2041  
2042  
2043  
2044  
2045  
2046  
2047  
2048  
2049  
2050  
2051  
2052  
2053  
2054  
2055  
2056  
2057  
2058  
2059  
2060  
2061  
2062  
2063  
2064  
2065  
2066  
2067  
2068  
2069  
2070  
2071  
2072  
2073  
2074  
2075  
2076  
2077  
2078  
2079  
2080  
2081  
2082  
2083  
2084  
2085  
2086  
2087  
2088  
2089  
2090  
2091  
2092  
2093  
2094  
2095  
2096  
2097  
2098  
2099  
2100  
2101  
2102  
2103  
2104  
2105  
2106  
2107  
2108  
2109  
2110  
2111  
2112  
2113  
2114  
2115  
2116  
2117  
2118  
2119  
2120  
2121  
2122  
2123  
2124  
2125  
2126  
2127  
2128  
2129  
2130  
2131  
2132  
2133  
2134  
2135  
2136  
2137  
2138  
2139  
2140  
2141  
2142  
2143  
2144  
2145  
2146  
2147  
2148  
2149  
2150  
2151  
2152  
2153  
2154  
2155  
2156  
2157  
2158  
2159  
2160  
2161  
2162  
2163  
216

VGEN.P-058-US  
PATENT APPLICATION

TTTCACGAAC AACGCGACAA

[SEQ ID No. 32]

Site of Specific Hybridization: nt 590-609

Maximum fragment size: 600 bp

5 Pathogen Name: Mycobacterium tuberculosis

Gene: IS6110

Forward Primer:T5

CTCGTCCAGC GCCGCTTCGG

[SEQ ID No. 33]

Site of Specific Hybridization: nt 758-788

Reverse Primer:T4

CCTGCGAGCG TAGGCGTCGG

[SEQ ID No. 34]

Site of Specific Hybridization: nt 881-862

Maximum fragment size: 123 bp

15 Pathogen Name: Rickettsia rickettsii (Rocky Mountain spotted fever)

Gene: 17 K Da Ag Gene

Forward Primer:TZ15

TTCTCAATTC GGTAAGGC

[SEQ ID No. 35]

Site of Specific Hybridization: nt 191-209

20 Reverse Primer :TZ16

ATATTGACCA GTGCTATTTT

[SEQ ID No. 36]

Site of Specific Hybridization: nt 437-419

Maximum fragment size: 247 bp

25 Pathogen Name: Ehrlichia chaffeensis

Gene: 16s rDNA

Forward Primer: HE1

CAATTGCTTA TAACCTTTTG GTTATAAAT

[SEQ ID No. 37]

Site of Specific Hybridization: nt 49-77

Reverse Primer:HE3

TATAGGTACC GTCATTATCT TCCCTAT

[SEQ ID No. 38]

5

Site of Specific Hybridization: nt 438-412

Maximum fragment size: 390 bp

Pathogen Name: *Borrelia burgdorferi* (Lyme disease)

Gene: Outer Surface Protein A

10

Forward Primer:OSPA149

TTATGAAAAA ATATTTATTG GGAAT

[SEQ ID No. 39]

Site of Specific Hybridization: nt 1

Reverse Primer: OSPA319

CTTTAAGCTC AAGCTTGTCT ACTGT

[SEQ ID No. 40]

Site of Specific Hybridization: nt 193

Maximum fragment size: 193 bp

Pathogen Name: *Borrelia burgdorferi* (Lyme disease)

Gene: Outer Surface Protein A

20

Forward Primer:OSPA4

CTGCAGCTTG GAATTCAGGC ACTTC

[SEQ ID No. 41]

Site of Specific Hybridization: nt 638

Reverse Primer : OSPA2

GTTTTGTAAT TTCAACTGCT GACC

[SEQ ID No. 42]

25

Site of Specific Hybridization: nt 793

Maximum fragment size: 156 bp

Pathogen Name: *Borrelia burgdorferi* (Lyme disease)

Gene: 16s rDNA

Forward Primer:DD06

ATCTGTTACC AGCATGTAAT

[SEQ ID No. 43]

Site of Specific Hybridization: nt 1105

Reverse Primer:DD02

CCCTCACTAA ACATACCT

[SEQ ID No. 44]

Site of Specific Hybridization: nt 1472

Maximum fragment size: 368 bp

Pathogen Name: *Borrelia burgdorferi* (Lyme disease)

Gene: Flagellin

Forward Primer:FLA1

GATGATGCTG CTGGCATGGG AGTTTCTGG

[SEQ ID No. 45]

Site of Specific Hybridization: nt 121

Reverse Primer: FLA3

CTGTCTGCAT CTGAATATGT GCCGTTACCT G

[SEQ ID No. 46]

Site of Specific Hybridization: nt 320

Maximum fragment size: bp

Pathogen Name: *Yersinia pestis* (the bubonic plague)

Gene: 9.5 kb pesticin plasmid

Forward Primer: Yp1

ATCTTACTTT CCGTGAGAAG

[SEQ ID No. 47]

Site of Specific Hybridization: nt 971-990

Reverse Primer: Yp2

CTTGATGTT GAGCTTCCTA

[SEQ ID No. 48]

Site of Specific Hybridization: nt 1450-1431

Maximum fragment size: 478 bp

Pathogen Name: *Treponema pallidum* (venereal syphilis)

5 Gene: 47-kDA gene

Forward Primer: 47-3

TTGTGGTAGA CACGGTGGGT AC

[SEQ ID No. 49]

Site of Specific Hybridization: nt 692 - 713

Reverse Primer: 47-4

10 TGATCGCTGA CAAGCTTAGG CT

[SEQ ID No. 50]

Site of Specific Hybridization: nt 1187-1166

Maximum fragment size: 496 bp

Pathogen Name: *Treponema pallidum* (venereal syphilis)

15 Gene: 16S rDNA

Forward Primer: Tpr3

CTCAGAGATG AGCCTGCGAC CATT

[SEQ ID No. 51]

Site of Specific Hybridization: nt 230

Reverse Primer: TPr4

20 GCATTCCCTC CCGTCCTCAT TCTTC

[SEQ ID No. 52]

Site of Specific Hybridization: nt 480

Maximum fragment size: 251 bp

25 Pathogen Name: *Chlamydia trachomatis* (infection of mucosal surfaces)

Gene: MOMP

Forward Primer: CT.0005

GATAGCGAGC ACAAAGAGAG CTAA

[SEQ ID No. 53]

Site of Specific Hybridization: nt 67

Reverse Primer: CT.06

TTCACATCTG TTTGCAAAAC ACGGTCGAAA ACAAAG

[SEQ ID No. 54]

5 Site of Specific Hybridization: nt 347

Maximum fragment size: 281 bp

Pathogen Name: Chlamydia pneumoniae (respiratory disease)

Gene: 474bp PST fragment

10 Forward Primer: HL-1

GTTGTTCATG AAGGCCTACT

[SEQ ID No. 55]

Site of Specific Hybridization: nt 30-49

Reverse Primer: HR-1

TGCATAACCT ACGGTGTGTT

[SEQ ID No. 56]

15 Site of Specific Hybridization: nt 467-448

Maximum fragment size: 438 bp

Pathogen Name: Mycoplasma pneumoniae (respiratory disease)

Gene: genomic

20 Forward Primer: MP5-1

GAAGCTTATG GTACAGGTTG G

[SEQ ID No. 57]

Reverse Primer: MP5-2

ATTACCATCC TTGTTGTAAG

[SEQ ID No. 58]

Maximum fragment size: 144 bp

25

Pathogen Name: Mycoplasma speciation (Universal Primers for 8 most common  
Mycoplasma species)



Gene: 16S rDNA

Forward Primer: Primer A

GGCGAATGGG TGAGTAACAC G

[SEQ ID No. 59]

Site of Specific Hybridization: nt 87

5 Reverse Primer: Primer B

CGGATAACGC TTGCGACCTA TG

[SEQ ID No. 60]

Site of Specific Hybridization: nt 550

Maximum fragment size: 464 bp

10 Pathogen Name: Legionella pneumophila (wound infection, respiratory disease)

Gene:

Forward Primer: LEG1

GCTATGAGGA ATCTCGCTG

[SEQ ID No. 61]

Reverse Primer: LEG2

15 CTGGCTTCTT CCAGCTTCA

[SEQ ID No. 62]

Maximum fragment size: 800 bp

Pathogen Name: Legionella dumoffii (wound infection, respiratory disease)

Gene:

20 Forward Primer: LDBKS1

ATACACGTGG TGGAGGTAC

[SEQ ID No. 63]

Reverse Primer: LDBKS2

GCGGGCAATA TCTTGCATC

[SEQ ID No. 64]

Maximum fragment size: 1000 bp

25 Pathogen Name: Mycoplasma fermentans

Gene: IS-like element

Forward Primer:RW005

GGTTATTCGA TTTCTAAATC GCCT

[SEQ ID No. 65]

Site of Specific Hybridization: nt 1116

Reverse Primer:RW004

5 GGACTATTGT CTAAACAATT TCCC

[SEQ ID No. 66]

Site of Specific Hybridization: nt 1321

Maximum fragment size: 206 nt

Pathogen Name: Ehrlichia

Gene: 16S rDNA

Forward Primer: 8F

AGTTTGATCA TGGCTCAG

[SEQ ID No. 67]

Site of Specific Hybridization: nt 32

Reverse Primer:GA1UR

15 GAGTTTGCCG GGA CTTCTTC T

[SEQ ID No. 68]

Site of Specific Hybridization: nt (about 400)

Maximum fragment size: (about 400 nt)

20 Viruses

Human Immunodeficiency Virus Type 1 (HIV-1)

Gene: gag

Forward Primer:SK462

25 AGTTGGAGGA CATCAAGCAG CCATGCAAAT

[SEQ ID No. 69]

Site of Specific Hybridization:1366-1395: nt

Reverse Primer:SK431

TGCTATGTCA GTTCCCCTTG GTTCTCT

[SEQ ID No. 70]

Site of Specific Hybridization: nt 1507-1481

Maximum fragment size: 142 nt

5

Human T-Cell Lymphotropic Virus Type 1 (HTLV-1)

Gene: POL

Forward Primer: POL1

CCCGGGCCCC CTGACTTGTC

[SEQ ID No. 71]

Site of Specific Hybridization: nt 2802-2821

Reverse Primer: POL3

GCTTTCAGTG TCCCACAGCAG

[SEQ ID No. 72]

Site of Specific Hybridization: nt 2916-2936

Maximum fragment size: 237 nt

Hepatitis B Virus (HBV)

Gene: surface antigen

Forward Primer: Primer 1

CAAGGTATGT TGCCCGTTTG

[SEQ ID No. 73]

Site of Specific Hybridization: nt 329-348

Reverse Primer: Primer 2

AAAGCCCTGC GAACCACTGA

[SEQ ID No. 74]

Site of Specific Hybridization: nt 587-568

Maximum fragment size: 259 nt

Hepatitis C Virus (HCV)

Gene: 5'UT

Forward Primer:5PUT c1-a

CCCAACACTA CTCGGCTAG

[SEQ ID No. 75]

Site of Specific Hybridization: nt -74--92

Reverse Primer:5PUT 1-s

5 AACTACTGTC TTCACGCAGA AAGC

[SEQ ID No. 76]

Site of Specific Hybridization: nt -266--289

Maximum fragment size: 216 nt

Herpes simplex virus (HSV)

Gene: DNA polymerase gene

Forward Primer: HSV-3

TACATCGGCG TCATCTGCGG GG

[SEQ ID No. 77]

Site of Specific Hybridization: nt 2821-2842

Reverse Primer: HSV-4

15 CAGTTCGGCG GTGAGGACAA AG

[SEQ ID No. 78]

Site of Specific Hybridization: nt 3090-3111

Maximum fragment size: 290 nt

Herpesvirus 6

20 Gene:

Forward Primer:H6-6

AAGCTTGCAC AATGCCAAAA AACAG

[SEQ ID No. 79]

Reverse Primer:H6-7

CTCGAGTATG CCGAGACCCC TAATC

[SEQ ID No. 80]

25 Maximum fragment size: 223 nt

Herpesvirus 7

Gene:

Forward Primer:HV7

TATCCCAGCT GTTTTCATAT AGTAAC

[SEQ ID No. 81]

Reverse Primer: HV8

5 GCCTTGCGGT AGCACTAGAT TTTTGTG

[SEQ ID No. 82]

Maximum fragment size: 186 nt

Epstein-Barr Virus

Gene: EBNA2

10 Forward Primer:E2p1

AAGGATGCCT GGACACAAGA

[SEQ ID No. 83]

Site of Specific Hybridization: nt 1813-1833

Reverse Primer:E2p2

15 TGGTGCTGCT GGTGGTGGCA AT

[SEQ ID No. 84]

Site of Specific Hybridization: nt 2409-2388

Maximum fragment size: 596 nt

Cytomegalovirus (CMV) (member of Herpesviridae)

Gene: CMV IE gene

20 Forward Primer:CMV1

CCTAGTGTGG ATGACCTACG GGCCA

[SEQ ID No. 85]

Site of Specific Hybridization: nt 1234-1258

Reverse Primer:CMV2

25 CAGACACAGT GTCCTCCCGC TCCTC

[SEQ ID No. 86]

Site of Specific Hybridization: nt 1459-1483

Maximum fragment size: 249 nt

Varicella-Zoster Virus (VZV) (for Chicken Pox)

Gene: unique genomic fragment

Forward Primer:VZ7

ATGTCCGTAC AACATCAACT

[SEQ ID No. 87]

5 Site of Specific Hybridization: nt 3377-3396

Reverse Primer:VZ8

CGATTTTCCA AGAGAGACGC

[SEQ ID No. 88]

Site of Specific Hybridization: nt 3643-3624

Maximum fragment size: 267 nt

10

JC Virus (JCV) distinguishing from BK virus and simian virus 40

Gene: T antigen

Forward Primer:P5

AGTCTTTAGG GTCTTCTACC

[SEQ ID No. 89]

15 Site of Specific Hybridization: nt 4255-4274

Reverse Primer:P6

GGTGCCAACC TATGGAACAG

[SEQ ID No. 90]

Site of Specific Hybridization: nt 4427-4408

Maximum fragment size: 172 nt

20

Parvovirus B19

Gene: VP Protein

Forward Primer: Z

GGAACAGACT TAGAGCTTAT TC

[SEQ ID No. 91]

25 Site of Specific Hybridization: nt 2537

Reverse Primer: Y

GCTTGTGTAA GTCTTCACTA G

[SEQ ID No. 92]

Site of Specific Hybridization: nt 2774

Maximum fragment size: 259 nt

Influenza A (Orthomyxoviridae)

5 Gene: hemagglutinin H2

Forward Primer:AH2B

CAATAGCTGG TTTTATAGAA [SEQ ID No. 93]

Site of Specific Hybridization: nt 1077

Reverse Primer:AH2CII

10 TTATCATACA GATTCTTGAC [SEQ ID No. 94]

Site of Specific Hybridization: nt 1425

Maximum fragment size: 349 nt

Influenza B (Orthomyxoviridae)

15 Gene: Matrix Protein

Forward Primer: BMPB

GAAGGCAAAG CAGAACTAGC [SEQ ID No. 95]

Site of Specific Hybridization: nt 79

Reverse Primer: BMPCII

20 TGGCCTTCTG CTATTTCAAA [SEQ ID No. 96]

Site of Specific Hybridization: nt 380

Maximum fragment size: 302 nt

Influenza C (Orthomyxoviridae)

25 Gene: hemagglutinin

Forward Primer:CHAB

GTGCAAACCTG CATCTTGTGG [SEQ ID No. 97]

Site of Specific Hybridization: nt 705

Reverse Primer:CHACII

CTCATTTCTT GATCTCCATG

[SEQ ID No. 98]

Site of Specific Hybridization: nt 1145

5 Maximum fragment size: 441 nt

Rotavirus

Gene: vp7

Forward Primer:A2

10 GGACCAAGAG AAAACGTAGC

[SEQ ID No. 99]

Site of Specific Hybridization: nt 805

Reverse Primer:A4

GGTCACATCA TACAATTCTA ATCTAAG

[SEQ ID No. 100]

Site of Specific Hybridization: nt 1062

Maximum fragment size: 257 nt

Human Adenovirus

Gene: Hexon gene

Forward Primer:A2H/pcr 4R

20 ATGACTTTTG AGGTGGATCC CATGGA

[SEQ ID No. 101]

Reverse Primer:A2H/pcr 1

GCCGAGAAGG GCGTGCGCAG GTA

[SEQ ID No. 102]

Maximum fragment size: 134 nt

25 Rubella Virus

Gene: 40S ssRNA

Forward Primer:Ru2



TGCTTTGCCC CATGGGACCT CGAG

[SEQ ID No. 103]

Site of Specific Hybridization: nt 1990-2013

Reverse Primer:Ru3

GGCGAACACG CTCATCACGG T

[SEQ ID No. 104]

5 Site of Specific Hybridization: nt 2310-2290

Maximum fragment size: 321 nt

Human Enteroviruses

Gene: 5'NTR

Forward Primer:MD91

CCTCCGGCCC CTGAATGCGG CTAAT

[SEQ ID No. 105]

Site of Specific Hybridization: nt 444-468

Reverse Primer:MD90

ATTGTCACCA TAAGCAGCCA

[SEQ ID No. 106]

Site of Specific Hybridization: nt 577-596

Maximum fragment size: 154 nt

Genital Human Papillomavirus (HPV)

Gene: L1 gene

Forward Primer:MY11

GCMCAGGGWC ATAAYAATGG

[SEQ ID No. 107]

Site of Specific Hybridization: nt 6582

Reverse Primer:MY09

CGTCCMAARG GAWACTGATC

[SEQ ID No. 108]

25 Site of Specific Hybridization: nt 7033

Maximum fragment size: 450 nt

Hantavirus

Gene: M segment

Forward Primer:Har M 30+

CACTGAATAA GAGGATACAA GAATGG

[SEQ ID No. 109]

Site of Specific Hybridization: nt 30

Reverse Primer:Har M 403-

GGAGGAATAT TACATGTGCC TTT

[SEQ ID No. 110]

Site of Specific Hybridization: nt 403

Maximum fragment size: 374 nt

Fungi

Cryptococcus neoformans (Universal fungal primers)

Gene:

Forward Primer: ITS1

TCCGTAGGTG AACCTGCGA

[SEQ ID No. 111]

Reverse Primer:ITS4

TCCTCCGCTT ATTGATATGC

[SEQ ID No. 112]

Maximum fragment size: 600 nt

Pneumocystis carinii

Gene: 5S rDNA

Forward Primer:5S Sense

AGTTACGGCC ATACCTCAGA

[SEQ ID No. 113]

Reverse Primer:5S Antisense

AAAGCTACAG CACGTCGTAT

[SEQ ID No. 114]

Maximum fragment size: 120 nt

Fungal Pathogens (*Histoplasma capsulatum*, *Blastomyces dermatitidis*, *Coccidioides immitis* *Trichophyton rubrum*)

5 Gene: 18S rDNA

Forward Primer: NS3

GCAAGTCTGG TGCCAGCAGC C

[SEQ ID No. 115]

Site of Specific Hybridization: nt 551

Reverse Primer: RDR116

10 CCGTCAATTC CTTTATGTTT CAGCCTT

[SEQ ID No. 116]

Site of Specific Hybridization: nt 1149

Maximum fragment size: 599 nt

15 Protozoa

*Trypanosoma cruzi*

Gene: kinetoplast

Forward Primer: S35

20 AAATAATGKA CGGGTGAGAT GCATGA

[SEQ ID No. 117]

Reverse Primer: S36

GGGTTCGATT GGGGTTGGTG T

[SEQ ID No. 118]

Maximum fragment size: 330 nt

25 *Leishmania* species

Gene: kinetoplast

Forward Primer: 13A

GTGGGGGAGG GGC GTTCT

[SEQ ID No. 119]

Reverse Primer:13B

ATTTTACACC AACCCCCAGT T

[SEQ ID No. 120]

Maximum fragment size: 120 nt

5

Plasmodium (genus specific)

Gene: Nuclear small subunit rDNA

Forward Primer: 566R

GGATAACTAC GGAAAAGCTG TAGC

[SEQ ID No. 121]

or Forward Primer: 570R

CGACTTCTCC TTCCTTTAAA AGATAGG

[SEQ ID No. 122]

Reverse Primer:567R

GTTCAAGATT AATAATTGCA ATAATCTATC CC

[SEQ ID No. 123]

Maximum fragment size: about 500 nt

10  
15  
20  
25  
30  
35  
40  
45  
50  
55  
60  
65  
70  
75  
80  
85  
90  
95  
100  
105  
110  
115  
120  
125  
130  
135  
140  
145  
150  
155  
160  
165  
170  
175  
180  
185  
190  
195  
200  
205  
210  
215  
220  
225  
230  
235  
240  
245  
250  
255  
260  
265  
270  
275  
280  
285  
290  
295  
300  
305  
310  
315  
320  
325  
330  
335  
340  
345  
350  
355  
360  
365  
370  
375  
380  
385  
390  
395  
400  
405  
410  
415  
420  
425  
430  
435  
440  
445  
450  
455  
460  
465  
470  
475  
480  
485  
490  
495  
500  
505  
510  
515  
520  
525  
530  
535  
540  
545  
550  
555  
560  
565  
570  
575  
580  
585  
590  
595  
600  
605  
610  
615  
620  
625  
630  
635  
640  
645  
650  
655  
660  
665  
670  
675  
680  
685  
690  
695  
700  
705  
710  
715  
720  
725  
730  
735  
740  
745  
750  
755  
760  
765  
770  
775  
780  
785  
790  
795  
800  
805  
810  
815  
820  
825  
830  
835  
840  
845  
850  
855  
860  
865  
870  
875  
880  
885  
890  
895  
900  
905  
910  
915  
920  
925  
930  
935  
940  
945  
950  
955  
960  
965  
970  
975  
980  
985  
990  
995  
1000

Entamoeba histolytica (amoebic dysentery)

Gene: SSU rDNA

Forward Primer:Psp5

GGCCAATTCA TTCAATGAAT TGAG

[SEQ ID No. 124]

Site of Specific Hybridization: nt 200

Reverse Primer:Psp3

CTCAGATCTA GAAACAATGC TTCTC

[SEQ ID No. 125]

Site of Specific Hybridization: nt 1075

Maximum fragment size: 876 nt

25

Babesia microti

Gene: SS rDNA

Forward Primer:Bab1

CTTAGTATAA GCTTTTATAC AGC

[SEQ ID No. 126]

Site of Specific Hybridization: nt 38-60

Reverse Primer:Bab4

5 ATAGGTCAGA AACTTGAATG ATACA

[SEQ ID No. 127]

Site of Specific Hybridization: nt 251-275

Maximum fragment size: 238 nt

Giardia lamblia

Gene: 18S rDNA gene

Forward Primer:JW1

GCGCACCAGG AATGTCTTGT

[SEQ ID No. 128]

Site of Specific Hybridization: nt 1251-1270

Reverse Primer:JW2

15 TCACCTACGG ATACCTTGTT

[SEQ ID No. 129]

Site of Specific Hybridization: nt 1433-1414

Maximum fragment size: 183 nt

Pathogen Name: Cryptosporidium oocyst detection

20 Gene: 18S rDNA

Forward Primer: CP1

CCGAGTTTGA TCCAAAAGT TACGAA

[SEQ ID No. 130]

Reverse Primer: CP2

TAGCTCCTCA TATGCCTTAT TGAGTA

[SEQ ID No. 131]

25 Maximum fragment size: 452 nt

Pathogen Name: Cyclospora and Eimeria species

Gene: 18S rDNA

Forward Primer: CYC3FE

GGAATTCCTT CCGAGCTTCG CTGCGT

[SEQ ID No. 132]

Site of Specific Hybridization: nt 685-704

5 Reverse Primer: CYC4RB

CGGGATCCCG TCTTCAAACC CCCTACTG

[SEQ ID No. 133]

Site of Specific Hybridization: nt 978-959

Maximum fragment size: 294 nt

#### Identification of Bacterial Toxin Genes

Pathogen Name: *Vibrio cholerae* 01 containing cholera toxin gene (epidemic cholera)

Gene: CTXA

Forward Primer: CTX2

CGGGCAGATT CTAGACCTCC TG

[SEQ ID No. 134]

Site of Specific Hybridization: nt 73-94

Reverse Primer: CTX3

CGATGATCTT GGAGCATTCC CAC

[SEQ ID No. 135]

Site of Specific Hybridization: nt 614-636

Maximum fragment size: 564 bp

Pathogen Name: Enterotoxigenic *Escherichia coli*

Gene: ST1a or ST1b

Forward Primer: ST1-1

TTAATAGCAC CCGGTACAAG CAGG

[SEQ ID No. 189]

Site of Specific Hybridization: nt 243-266

Reverse Primer: ST1-2

CTTGACTCTT CAAAAGAGAA AATTAC

[SEQ ID No. 136]

Site of Specific Hybridization: nt 127-144

Maximum fragment size: 147 bp

5

Pathogen Name: Enterotoxigenic Escherichia coli

Gene: LT1a or LT1b

Forward Primer: LT1a/b-1

TCTCTATRTG CAYACGGAGC

[SEQ ID No. 137]

Site of Specific Hybridization: nt 46-65

Reverse Primer: LT1-2

CCATACTGAT TGCCGCAAT

[SEQ ID No. 138]

Site of Specific Hybridization: nt 349-367

Maximum fragment size: 322 bp

10  
15  
20  
25  
30  
35  
40  
45  
50  
55  
60  
65  
70  
75  
80  
85  
90  
95  
100  
105  
110  
115  
120  
125  
130  
135  
140  
145  
150  
155  
160  
165  
170  
175  
180  
185  
190  
195  
200  
205  
210  
215  
220  
225  
230  
235  
240  
245  
250  
255  
260  
265  
270  
275  
280  
285  
290  
295  
300  
305  
310  
315  
320  
325  
330  
335  
340  
345  
350  
355  
360  
365  
370  
375  
380  
385  
390  
395  
400  
405  
410  
415  
420  
425  
430  
435  
440  
445  
450  
455  
460  
465  
470  
475  
480  
485  
490  
495  
500  
505  
510  
515  
520  
525  
530  
535  
540  
545  
550  
555  
560  
565  
570  
575  
580  
585  
590  
595  
600  
605  
610  
615  
620  
625  
630  
635  
640  
645  
650  
655  
660  
665  
670  
675  
680  
685  
690  
695  
700  
705  
710  
715  
720  
725  
730  
735  
740  
745  
750  
755  
760  
765  
770  
775  
780  
785  
790  
795  
800  
805  
810  
815  
820  
825  
830  
835  
840  
845  
850  
855  
860  
865  
870  
875  
880  
885  
890  
895  
900  
905  
910  
915  
920  
925  
930  
935  
940  
945  
950  
955  
960  
965  
970  
975  
980  
985  
990  
995

Pathogen Name: Enterotoxigenic Escherichia coli

Gene: SLTII

Forward Primer:SLTII-1

CTTCGGTATC CTATTCCCGG

[SEQ ID No. 139]

Site of Specific Hybridization: nt 288-307

Reverse Primer:SLTII-2

GGATGCATCT CTGGTCATTG

[SEQ ID No. 140]

Site of Specific Hybridization: nt 747-766

Maximum fragment size: 478 bp

25

Pathogen Name: Shigella species and enteroinvasive E. coli (diarrheal disease)

Gene: Invasion plasmid ial locus

VGEN.P-058-US  
PATENT APPLICATION

Forward Primer: Sh-1

CTGGATGGTA TGGTGAGG

[SEQ ID No. 141]

Reverse Primer: Sh-2

GGAGGCCAAC AATTATTTCC

[SEQ ID No. 142]

5 Maximum fragment size: 320 bp

Pathogen Name: *Helicobacter pylori* (formerly *Campylobacter pylori*)

Gene: genomic

Forward Primer: CAM-2

TAACAAACCG ATAATGGCGC

[SEQ ID No. 143]

Reverse Primer: CAM-4

CATCTTGTTA GAGGGATTGG

[SEQ ID No. 144]

Maximum fragment size: 203 bp

Pathogen Name: Toxigenic *Clostridium difficile*

Gene: rDNA

Forward Primer: PG-48

CTCTTGAAAC TGGGAGACTT GA

[SEQ ID No. 145]

Reverse Primer: B

CCGTCAATTC MTTTRAGTTT

[SEQ ID No. 146]

Maximum fragment size: 291 bp

Pathogen Name: Toxigenic *Clostridium difficile*

Gene: Toxin B

Forward Primer: YT-17

GGTGGAGCTT CAATTGGAGA G

[SEQ ID No. 147]



Reverse Primer: YT-18

GTGTAACCTA CTTTCATAAC ACCAG

[SEQ ID No. 148]

Maximum fragment size: 399 bp

5 Pathogen Name: Staphylococcus aureus toxins and virulence factors

Gene: sea

Forward Primer:SEA1

TTGGAAACGG TTAACGAA

[SEQ ID No. 149]

Site of Specific Hybridization: nt 490-509

Reverse Primer:SEA2

GAACCTTCCC ATCAAAAACA

[SEQ ID No. 150]

Site of Specific Hybridization: nt 610-591

Maximum fragment size: 120 bp

15 Pathogen Name: Staphylococcus aureus toxins and virulence factors

Gene: seb

Forward Primer:SEB1

TCGCATCAAA CTGACAAACG

[SEQ ID No. 151]

Site of Specific Hybridization: nt 634-653

Reverse Primer:SEB2

GCAGGTACTC TATAAGTGCC

[SEQ ID No. 152]

Site of Specific Hybridization: nt 1110-1091

Maximum fragment size: 478 bp

25 Pathogen Name: Staphylococcus aureus toxins and virulence factors

Gene: sec

Forward Primer: SEC1

GACATAAAAG CTAGGAATTT

[SEQ ID No. 153]

Site of Specific Hybridization: nt 676-695

Reverse Primer:SEC2

AAATCGGATT AACATTATCC

[SEQ ID No. 154]

5 Site of Specific Hybridization: nt 932-913

Maximum fragment size: 257 bp

Pathogen Name: Staphylococcus aureus toxins and virulence factors

Gene: sed

10 Forward Primer:SED1

CTAGTTTGGT AATATCTCCT

[SEQ ID No. 155]

Site of Specific Hybridization: nt 354-373

Reverse Primer:SED2

TAATGCTATA TCTTATAGGG

[SEQ ID No. 156]

15 Site of Specific Hybridization: nt 671-652

Maximum fragment size: 317 bp

Pathogen Name: Staphylococcus aureus toxins and virulence factors

Gene: see

20 Forward Primer:SEE1

TAGATAAAGT TAAAACAAGC

[SEQ ID No. 157]

Site of Specific Hybridization: nt 491-510

Reverse Primer:SEE2

TAACTTACCG TGGACCCTTC

[SEQ ID No. 158]

25 Site of Specific Hybridization: nt 659-640

Maximum fragment size: 170 bp

Pathogen Name: Staphylococcus aureus toxins and virulence factors

Gene: tss

Forward Primer:TSST1

ATGGCAGCAT CAGCTTGATA [SEQ ID No. 159]

5 Site of Specific Hybridization: nt 251-270

Reverse Primer:TSST2

TTTCCAATAA CCACCCGTTT [SEQ ID No. 160]

Site of Specific Hybridization: nt 600-581

Maximum fragment size: 350 bp

Pathogen Name: Staphylococcus aureus toxins and virulence factors

Gene: eta

Forward Primer:ETA1

CTAGTGCATT TGTTATTCAA [SEQ ID No. 161]

15 Site of Specific Hybridization: nt 374-393

Reverse Primer:ETA2

TGCATTGACA CCATAGTACT [SEQ ID No. 162]

Site of Specific Hybridization: nt 492-473

Maximum fragment size: 119 bp

Pathogen Name: Staphylococcus aureus toxins and virulence factors

Gene: etb

Forward Primer:ETB1

ACGGCTATAT ACATTCAATT [SEQ ID No. 163]

25 Site of Specific Hybridization: nt 51-70

Reverse Primer:ETB2

TCCATCGATA ATATACCTAA [SEQ ID No. 164]

Site of Specific Hybridization: nt 250-231

Maximum fragment size: 200 bp

Pathogen Name: Bacterial meningitis (Haemophilus influenzae, Neisseria meningitidis,  
Streptococcus pneumonia, S. agalactiae, Listeria monocytogenes, enteric bacteria, or  
Mycobacterium tuberculosis)

Gene: 16s rDNA

Forward Primer:RW01

AACTGGAGGA AGGTGGGGAT

[SEQ ID No. 165]

Reverse Primer:DG74

AGGAGGTGAT CCAACCGCA

[SEQ ID No. 166]

Maximum fragment size: 370 nt

Pathogen Name: Streptococcus pyogenes exotoxins (Streptococcal Toxic Shock Syndrome)

Gene: speC

Forward Primer:F

CCACCTTGAC TATTT

[SEQ ID No. 167]

Reverse Primer:R

TTAATTAGGA GGTA

[SEQ ID No. 168]

Maximum fragment size: 936 nt

Identification of Anti-Microbial Resistance Loci

Pathogen Name: Rifampin Resistance Mutations in Mycobacterium tuberculosis and M.  
leprae

Gene: rpoB

Forward Primer:rpoB105

CGTGGAGGCG ATCACACCGC AGACGT

[SEQ ID No. 169]

Reverse Primer:rpoB293

AGTGCGACGG GTGCACGTCG CGGACCT

[SEQ ID No. 170]

5 Maximum fragment size: 215 nt

Pathogen Name: Human Immunodeficiency Virus Drug Resistance

Gene: HIV Reverse Transcriptase

Forward Primer:A(35)

10 TTGGTTGCAC TTAAATTTT CCCATTAGTC CTATT

[SEQ ID No. 171]

Reverse Primer:NE-1(35)

CCTACTAACT TCTGTATGTC ATTGACAGTC CAGCT

[SEQ ID No. 172]

Maximum fragment size: 805 nt

15 Pathogen Name: erm Erythromycin Resistance Genes (in *S. aureus*, *E. coli*, or *Bacillus*  
*sphaericus*)

Gene: erm

Forward Primer:E1

GARATIGGII IIGGIAARGG ICA\*

[SEQ ID No. 173]

20 Reverse Primer:E2

AAYTGRTTYT TIGTRAA\*

[SEQ ID No. 174]

Maximum fragment size: 530 nt

\*I=inosine

25 Pathogen Name: Methicillin-Resistant *Staphylococcus*

Gene: mecA

Forward Primer:RSM 2647

AAAATCGATG GTAAAGGTTG GC

[SEQ ID No. 175]

Site of Specific Hybridization: nt 1282-1303

Reverse Primer: RSM 2648

AGTTCTGCAG TACCGGATTT GC

[SEQ ID No. 176]

5 Site of Specific Hybridization: nt 1814-1793

Maximum fragment size: 533 nt

Pathogen Name: Penicillinase-Producing *Neisseria gonorrhoeae*

Gene: TEM-1

10 Forward Primer:PPNG-L

AGTTATCTAC ACGACGG

[SEQ ID No. 177]

Reverse Primer:PPNG-R

GGCGTACTAT TCACTCT

[SEQ ID No. 178]

Maximum fragment size: 761 nt

Pathogen Name: Aminoglycoside-Modifying Enzymes

Gene: aacC1

Forward Primer:aacC1-1

ACCTACTCCC AACATCAGCC

[SEQ ID No. 179]

20 Reverse Primer:aacC1-2

ATATAGATCT CACTACGCGC

[SEQ ID No. 180]

Maximum fragment size: 169 nt

Pathogen Name: Extended Spectrum of Beta-lactamases

25 Gene: TEM-1

Forward Primer:Lag.Std.3

AGAGAATTAT GCAGTGC

[SEQ ID No. 181]

Site of Specific Hybridization: nt 560

Reverse Primer:Amp. Primer. 2

GACAGTTACC AATGCTTAAT CA

[SEQ ID No. 182]

Site of Specific Hybridization: nt 1074

5 Maximum fragment size: 514 nt

Pathogen Name: Fluoroquinolone Resistance mutations in Mycobacterium tuberculosis

Gene: gyrA

Forward Primer:GyrA1

CAGCTACATC GACTATGCGA

[SEQ ID No. 183]

Site of Specific Hybridization: nt 78-97

Reverse Primer:GyrA2

GGGCTTCGGT GTACCTCAT

[SEQ ID No. 184]

Site of Specific Hybridization: nt 379-397

Maximum fragment size: 320 nt

Pathogen Name: Isoniazid Resistance of Mycobacterium tuberculosis

Gene: katG

Forward Primer:katG904

AGCTCGTATG GCACCGGAAC

[SEQ ID No. 185]

Site of Specific Hybridization: nt 904

Reverse Primer:katG1523

TTGACCTCCC ACCCGACTTG

[SEQ ID No. 186]

Site of Specific Hybridization: nt 1523

25 Maximum fragment size: 620 nt

Pathogen Name: Vancomycin resistant Enterococci

VGEN.P-058-US  
PATENT APPLICATION

Gene: vanB

Forward Primer:VanB1

CATCGCCGTC CCCGAATTTC AAA

[SEQ ID No. 187]

Reverse Primer:VanB2

5 GATGCGGAAG ATACCGTGGC T

[SEQ ID No. 188]

Maximum fragment size: 297 nt

US 2014/0120950 A1



SEQUENCE LISTING

(1) GENERAL INFORMATION:

(I) APPLICANT: Leushner, James  
Hui, May  
Dunn, James M.  
LaCroix, Jean-Michel

(ii) TITLE OF INVENTION: METHOD, COMPOSITIONS AND KIT FOR DETECTION OF  
MICROORGANISMS AND BI-DIRECTIONAL SEQUENCING OF NUCLEIC ACID  
POLYMERS

(iii) NUMBER OF SEQUENCES: 189

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Oppedahl & Larson LLP

(B) STREET: P.O. Box 5270

(C) CITY: Frisco

(D) STATE: CO

(E) COUNTRY: US

(F) ZIP: 80443-5270

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage

(B) COMPUTER: IBM compatible

(C) OPERATING SYSTEM: MS DOS

(D) SOFTWARE: Word Perfect

(vi) CURRENT APPLICATION DATA :

(A) APPLICATION NUMBER:

(B) FILING DATE:

(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER:

(B) FILING DATE:

(viii) ATTORNEY/AGENT INFORMATION :

(A) NAME: Larson, Marina T.

(B) REGISTRATION NUMBER: 32,038

(C) REFERENCE/DOCKET NUMBER: VGEN.P-058-US

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (970) 668-2050

(B) TELEFAX: (970) 668-2082

(C) TELEX:

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Chlamydia trachomatis

(D) OTHER INFORMATION: primer for sequencing of cryptic plasmid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

TCCGGAGCGA GTTACGAAGA 20

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Chlamydia trachomatis

(D) OTHER INFORMATION: primer for sequencing of cryptic plasmid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

ATTCAATGCC CGGGATTGGT 20

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Chlamydia trachomatis

(D) OTHER INFORMATION: primer for sequencing of VS regions

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

CCGACCGCGT CTTGAAAACA GATGT 25

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Chlamydia trachomatis

(D) OTHER INFORMATION: primer for sequencing of VS regions

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

CACCCACATT CCCAGAGAGC T 21

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Chlamydia trachomatis

(D) OTHER INFORMATION: primer for sequencing of VS regions

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

CGTGCAGCTT TGTGGGAATG T 21

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Chlamydia trachomatis

(D) OTHER INFORMATION: primer for sequencing of VS regions

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

CTAGATTTCATCTTGTTCAA TTGC 24

(2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Chlamydia trachomatis

(D) OTHER INFORMATION: primer for sequencing of VS regions

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

AGCATGCGTR TKG GTTACTA YGG 23

(2) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Chlamydia trachomatis

(D) OTHER INFORMATION: primer for sequencing of VS regions

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

TGACTTTGTT TTCGACCGYG TTTT 24

(2) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Chlamydia trachomatis

(D) OTHER INFORMATION: primer for sequencing of VS regions

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

CTAAAGTYGC RCATCCACAT TCC 23

(2) INFORMATION FOR SEQ ID NO: 10:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: other nucleic acid  
(iii) HYPOTHETICAL: no  
(iv) ANTI-SENSE: no  
(v) FRAGMENT TYPE: internal  
(vi) ORIGINAL SOURCE:  
(A) ORGANISM: Chlamydia trachomatis  
(D) OTHER INFORMATION: primer for sequencing of VS regions  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:  
CATCCACATT CCCASARAGC TGC 23

(2) INFORMATION FOR SEQ ID NO: 11:  
(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 20  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: other nucleic acid  
(iii) HYPOTHETICAL: no  
(iv) ANTI-SENSE: no  
(v) FRAGMENT TYPE: internal  
(vi) ORIGINAL SOURCE:  
(A) ORGANISM: Chlamydia trachomatis  
(D) OTHER INFORMATION: primer for sequencing of cryptic plasmid  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:  
ATGCCCGGGA TTGGTTGATC 20



(2) INFORMATION FOR SEQ ID NO: 12:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Chlamydia trachomatis

(D) OTHER INFORMATION: primer for sequencing of VS regions

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

GGAGACTTTG TTTTCGACCG 20

(2) INFORMATION FOR SEQ ID NO: 13:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Chlamydia trachomatis

(D) OTHER INFORMATION: primer for sequencing of VS regions

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

CATTCCCACA AAGCTGCGCG 20

(2) INFORMATION FOR SEQ ID NO: 14:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Chlamydia trachomatis

(D) OTHER INFORMATION: primer for sequencing of VS regions

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

TTCCCACAAA GCTGCGCGAG 20

(2) INFORMATION FOR SEQ ID NO: 15:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Chlamydia trachomatis

(D) OTHER INFORMATION: primer for sequencing of VS regions

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

CCCACAAAGC TGCGCGAGCG 20

(2) INFORMATION FOR SEQ ID NO: 16:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Chlamydia trachomatis

(D) OTHER INFORMATION: primer for sequencing of ribosomal DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

ACCTTTCGGT TGAGGGAGAG TCTA 24

(2) INFORMATION FOR SEQ ID NO: 17:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Chlamydia trachomatis

(D) OTHER INFORMATION: primer for sequencing of ribosomal DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

GGACCAATTC TTATTCCCAA GCGA 24

(2) INFORMATION FOR SEQ ID NO: 18:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: HIV-1

(D) OTHER INFORMATION: primer for sequencing of HIV-1 protease gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

ATCACTCTTT GGCAACGACC 20

(2) INFORMATION FOR SEQ ID NO: 19:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: HIV-1

(D) OTHER INFORMATION: primer for sequencing of HIV-1 protease gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

CAGGAGCAGA TGATACAGTA TTAG 24

(2) INFORMATION FOR SEQ ID NO: 20:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: HIV-1

(D) OTHER INFORMATION: primer for sequencing of HIV-1 protease gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

CCATTCCTGG CTTTAATTTT ACTGG 25

(2) INFORMATION FOR SEQ ID NO: 21:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Human Papillomavirus

(D) OTHER INFORMATION: primer for sequencing of HPV

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

GCMCAGGGWC ATAAYAATGG 20

(2) INFORMATION FOR SEQ ID NO: 22:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Human Papillomavirus

(D) OTHER INFORMATION: primer for sequencing of HPV

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

CGTCCMAARG GAWACTGATC 20

(2) INFORMATION FOR SEQ ID NO: 23:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

TCAAAGAAT TGACGGGGGC 20

(2) INFORMATION FOR SEQ ID NO: 24:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

AGGCCCGGGA ACGTATTCAC 20

(2) INFORMATION FOR SEQ ID NO: 25:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

TGCCAGCAGC CGCGGTAA 18

(2) INFORMATION FOR SEQ ID NO: 26:



(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

GGACTACCAG GGTATCTAAT 20

(2) INFORMATION FOR SEQ ID NO: 27:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

GAGGAAGGTG GGGATGACGT 20

(2) INFORMATION FOR SEQ ID NO: 28:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: other nucleic acid  
(iii) HYPOTHETICAL: no  
(iv) ANTI-SENSE: no  
(v) FRAGMENT TYPE: internal  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

AGGCCCGGGA ACGTATTCAC 20

(2) INFORMATION FOR SEQ ID NO: 29:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: other nucleic acid  
(iii) HYPOTHETICAL: no  
(iv) ANTI-SENSE: yes  
(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

GAGAGTTTGA TCCTGGCTCA G 21

(2) INFORMATION FOR SEQ ID NO: 30:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: other nucleic acid  
(iii) HYPOTHETICAL: no  
(iv) ANTI-SENSE: no  
(v) FRAGMENT TYPE: internal  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

CCCACTGCTG CCTCCCGTAG 20

(2) INFORMATION FOR SEQ ID NO: 31:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: other nucleic acid  
(iii) HYPOTHETICAL: no  
(iv) ANTI-SENSE: yes  
(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

GAGAGTTTGA TCCTGGCTCA G 31

(2) INFORMATION FOR SEQ ID NO: 32:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

TTTCACGAAC AACGCGACAA 20

(2) INFORMATION FOR SEQ ID NO: 33:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

CTCGTCCAGC GCCGCTTCGG 20

(2) INFORMATION FOR SEQ ID NO: 34:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

CCTGCGAGCG TAGGCGTCGG 20

(2) INFORMATION FOR SEQ ID NO: 35:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

TTCTCAATTC GGTAAGGC 18

(2) INFORMATION FOR SEQ ID NO: 36:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

ATATTGACCA GTGCTATTTT 20

(2) INFORMATION FOR SEQ ID NO: 37:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

CAATTGCTTA TAACCTTTTG GTTATAAAT 29

(2) INFORMATION FOR SEQ ID NO: 38:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

TATAGGTACC GTCATTATCT TCCCTAT 27

(2) INFORMATION FOR SEQ ID NO: 39:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

TTATGAAAAA ATATTTATTG GGAAT 25

(2) INFORMATION FOR SEQ ID NO: 40:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

CTTTAAGCTC AAGCTTGTCT ACTGT 25

(2) INFORMATION FOR SEQ ID NO: 41:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

CTGCAGCTTG GAATTCAGGC ACTTC 41



(2) INFORMATION FOR SEQ ID NO: 42:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

GTTTTGTAAT TTCAACTGCT GACC 24

(2) INFORMATION FOR SEQ ID NO: 43:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:

ATCTGTTACC AGCATGTAAT 20

(2) INFORMATION FOR SEQ ID NO: 44:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:

CCCTCACTAA ACATACCT 18

(2) INFORMATION FOR SEQ ID NO: 45:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:

GATGATGCTG CTGGCATGGG AGTTTCTGG 29

(2) INFORMATION FOR SEQ ID NO: 46:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 31

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 46:

CTGTCTGCAT CTGAATATGT GCCGTTACCT G 31

(2) INFORMATION FOR SEQ ID NO: 47:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:

ATCTTACTTT CCGTGAGAAG 20

(2) INFORMATION FOR SEQ ID NO: 48:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:

CTTGGATGTT GAGCTTCCTA 20

(2) INFORMATION FOR SEQ ID NO: 49:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:

TTGTGGTAGA CACGGTGGGT AC 22

(2) INFORMATION FOR SEQ ID NO: 50:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:

TGATCGCTGA CAAGCTTAGG CT 22

(2) INFORMATION FOR SEQ ID NO: 51:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:

CTCAGAGATG AGCCTGCGAC CATT 24

(2) INFORMATION FOR SEQ ID NO: 52:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:

GCATTCCCTC CCGTCCTCAT TCTTC 25

(2) INFORMATION FOR SEQ ID NO: 53:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:

GATAGCGAGC ACAAAGAGAG CTAA 24

(2) INFORMATION FOR SEQ ID NO: 54:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 36

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:

TTCACATCTG TTTGCAAAAC ACGGTCGAAA ACAAAG 36

(2) INFORMATION FOR SEQ ID NO: 55:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:

GTTGTTCATG AAGGCCTACT 20

(2) INFORMATION FOR SEQ ID NO: 56:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:

TGCATAACCT ACGGTGTGTT 20

(2) INFORMATION FOR SEQ ID NO: 57:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:

GAAGCTTATG GTACAGGTTG G



(2) INFORMATION FOR SEQ ID NO: 58:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:

ATTACCATCC TTGTTGTAAG 20

(2) INFORMATION FOR SEQ ID NO: 59:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:

GGCGAATGGG TGAGTAACAC G 21

(2) INFORMATION FOR SEQ ID NO: 60:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:60:

CGGATAACGC TTGCGACCTA TG 22

(2) INFORMATION FOR SEQ ID NO: 61:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:

GCTATGAGGA ATCTCGCTG 19

(2) INFORMATION FOR SEQ ID NO: 62:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:62:

CTGGCTTCTT CCAGCTTCA 19

(2) INFORMATION FOR SEQ ID NO: 63:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:

ATACACGTGG TGGAGGTAC 19

(2) INFORMATION FOR SEQ ID NO: 64:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:

GCGGGCAATA TCTTGCATC 19

(2) INFORMATION FOR SEQ ID NO: 65:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:

GGTTATTCGA TTTCTAAATC GCCT 24

(2) INFORMATION FOR SEQ ID NO: 66:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:

GGACTATTGT CTAAACAATT TCCC 24

(2) INFORMATION FOR SEQ ID NO: 67:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:67:

AGTTTGATCA TGGCTCAG 18

(2) INFORMATION FOR SEQ ID NO: 68:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:68:

GAGTTTGCCG GGA CTTC T 21

(2) INFORMATION FOR SEQ ID NO: 69:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:69:

AGTTGGAGGA CATCAAGCAG CCATGCAAAT 30

(2) INFORMATION FOR SEQ ID NO: 70:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:70:

TGCTATGTCA GTTCCCCTTG GTTCTCT 27

(2) INFORMATION FOR SEQ ID NO: 71:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:71:

CCCGGGCCCC CTGACTTGTC 20

(2) INFORMATION FOR SEQ ID NO: 72:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:72:

GCTTTCAC TG TCCCACAGCA G 21

(2) INFORMATION FOR SEQ ID NO: 73:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:73:

CAAGGTATGT TGCCCGTTTG 20



(2) INFORMATION FOR SEQ ID NO: 74:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:74:

AAAGCCCTGC GAACCACTGA 20

(2) INFORMATION FOR SEQ ID NO: 75:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:75:

CCCAACACTA CTCGGCTAG 19

(2) INFORMATION FOR SEQ ID NO: 76:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:76:

AACTACTGTC TTCACGCAGA AAGC 24

(2) INFORMATION FOR SEQ ID NO: 77:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:77:

TACATCGGCG TCATCTGCGG GG 22

(2) INFORMATION FOR SEQ ID NO: 78:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:78:

CAGTTCGGCG GTGAGGACAA AG 22

(2) INFORMATION FOR SEQ ID NO: 79:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:79:

AAGCTTGCAC AATGCCAAAA AACAG 25

(2) INFORMATION FOR SEQ ID NO: 80:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:80:

CTCGAGTATG CCGAGACCCC TAATC 25

(2) INFORMATION FOR SEQ ID NO: 81:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 26

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:81:

TATCCCAGCT GTTTTCATAT AGTAAC 26

(2) INFORMATION FOR SEQ ID NO: 82:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 26

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:82:

GCCTTGCGGT AGCACTAGAT TTTTGT 26

(2) INFORMATION FOR SEQ ID NO: 83:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:83:

AAGGATGCCT GGACACAAGA 20

(2) INFORMATION FOR SEQ ID NO: 84:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:84:

TGGTGCTGCT GGTGGTGGCA AT 22

(2) INFORMATION FOR SEQ ID NO: 85:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:85:

CCTAGTGTGG ATGACCTACG GGCCA 25

(2) INFORMATION FOR SEQ ID NO: 86:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:86:

CAGACACAGT GTCCTCCCGC TCCTC 25

(2) INFORMATION FOR SEQ ID NO: 87:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:87:

ATGTCCGTAC AACATCAACT 20

(2) INFORMATION FOR SEQ ID NO: 88:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:88:

CGATTTTCCA AGAGAGACGC 20

(2) INFORMATION FOR SEQ ID NO: 89:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:89:

AGTCTTTAGG GTCTTCTACC 20



(2) INFORMATION FOR SEQ ID NO: 90:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:90:

GGTGCCAACC TATGGAACAG 20

(2) INFORMATION FOR SEQ ID NO: 91:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:91:

GGAACAGACT TAGAGCTTAT TC 22

(2) INFORMATION FOR SEQ ID NO: 92:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:92:

GCTTGTGTAA GTCTTCACTA G 21

(2) INFORMATION FOR SEQ ID NO: 93:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:93:

CAATAGCTGG TTTTATAGAA 20

(2) INFORMATION FOR SEQ ID NO: 94:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:94:

TTATCATACA GATTCTTGAC 20

(2) INFORMATION FOR SEQ ID NO: 95:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:95:

GAAGGCAAAG CAGAACTAGC 20

(2) INFORMATION FOR SEQ ID NO: 96:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:96:

TGGCCTTCTG CTATTTCAAA 20

(2) INFORMATION FOR SEQ ID NO: 97:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:97:

GTGCAAACTG CATCTTGTGG 20

(2) INFORMATION FOR SEQ ID NO: 98:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:98:

CTCATTTCTT GATCTCCATG 20

(2) INFORMATION FOR SEQ ID NO: 99:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:99:

GGACCAAGAG AAAACGTAGC 20

(2) INFORMATION FOR SEQ ID NO: 100:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:100:

GGTCACATCA TACAATTCTA ATCTAAG 27

(2) INFORMATION FOR SEQ ID NO: 101:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 26

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:101:

ATGACTTTTG AGGTGGATCC CATGGA 26

(2) INFORMATION FOR SEQ ID NO: 102:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:102:

GCCGAGAAGG GCGTGCGCAG GTA 23

(2) INFORMATION FOR SEQ ID NO: 103:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 103:

TGCTTTGCCC CATGGGACCT CGAG 24

(2) INFORMATION FOR SEQ ID NO: 104:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:104:

GGCGAACACG CTCATCACGG T 21

(2) INFORMATION FOR SEQ ID NO: 105:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:105:

CCTCCGGCCC CTGAATGCGG CTAAT 25



(2) INFORMATION FOR SEQ ID NO: 106:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:106:

ATTGTCACCA TAAGCAGCCA 20

(2) INFORMATION FOR SEQ ID NO: 107:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:107:

GCMCAGGGWC ATAAYAATGG 20

(2) INFORMATION FOR SEQ ID NO: 108:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 108:

CGTCCMAARG GAWACTGATC 20

(2) INFORMATION FOR SEQ ID NO: 109:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 26

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 109:

CACTGAATAA GAGGATACAA GAATGG 26

(2) INFORMATION FOR SEQ ID NO: 110:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:110:

GGAGGAATAT TACATGTGCC TTT 23

(2) INFORMATION FOR SEQ ID NO: 111:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:111:

TCCGTAGGTG AACCTGCGA 19

(2) INFORMATION FOR SEQ ID NO: 112:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:112:

TCCTCCGCTT ATTGATATGC 20

(2) INFORMATION FOR SEQ ID NO: 113:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:113:

AGTTACGGCC ATACCTCAGA 20

(2) INFORMATION FOR SEQ ID NO: 114:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:114:

AAAGCTACAG CACGTCGTAT 20

(2) INFORMATION FOR SEQ ID NO: 115:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:115:

GCAAGTCTGG TGCCAGCAGC C 21

(2) INFORMATION FOR SEQ ID NO: 116:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:116:

CCGTCAATTC CTTTATGTTT CAGCCTT 27

(2) INFORMATION FOR SEQ ID NO: 117:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 26

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:117:

AAATAATGKA CGGGTGAGAT GCATGA 26

(2) INFORMATION FOR SEQ ID NO: 118:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:118:

GGGTTCGATT GGGGTTGGTG T 21

(2) INFORMATION FOR SEQ ID NO: 119:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:119:

GTGGGGGAGG GGC GTTCT 18

(2) INFORMATION FOR SEQ ID NO: 120:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:120:

ATTTTACACC AACCCCCAGT T 21

(2) INFORMATION FOR SEQ ID NO: 121:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:121:

GGATAACTAC GGAAAAGCTG TAGC 24



(2) INFORMATION FOR SEQ ID NO: 122:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 122:

CGACTTCTCC TTCCTTTAAA AGATAGG 27

(2) INFORMATION FOR SEQ ID NO: 123:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 32

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:123:

GTTCAAGATT AATAATTGCA ATAATCTATC CC 32

[SEQ ID No. 123]

Maximum fragment size: about 500 nt

(2) INFORMATION FOR SEQ ID NO: 124:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:124:

GGCCAATTCA TTCAATGAAT TGAG 24

(2) INFORMATION FOR SEQ ID NO: 125:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:125:

CTCAGATCTA GAAACAATGC TTCTC 25

(2) INFORMATION FOR SEQ ID NO: 126:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:126:

CTTAGTATAA GCTTTTATAC AGC 23

(2) INFORMATION FOR SEQ ID NO: 127:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 127:

ATAGGTCAGA AACTTGAATG ATACA 25

(2) INFORMATION FOR SEQ ID NO: 128:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:128:

GCGCACCAGG AATGTCTTGT 20

(2) INFORMATION FOR SEQ ID NO: 129:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:129:

TCACCTACGG ATACCTTGTT 20

(2) INFORMATION FOR SEQ ID NO: 130:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 26

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:130:

CCGAGTTTGA TCCAAAAAGT TACGAA 26

(2) INFORMATION FOR SEQ ID NO: 131:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 26

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:131:

TAGCTCCTCA TATGCCTTAT TGAGTA 26

(2) INFORMATION FOR SEQ ID NO: 132:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 26

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:132:

GGAATTCCTT CCGAGCTTCG CTCGGT 26

(2) INFORMATION FOR SEQ ID NO: 133:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 28

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:133:

CGGGATCCCG TCTTCAAACC CCCTACTG 28

(2) INFORMATION FOR SEQ ID NO: 134:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:134:

CGGGCAGATT CTAGACCTCC TG 22

(2) INFORMATION FOR SEQ ID NO: 135:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:135:

CGATGATCTT GGAGCATTCC CAC 23

(2) INFORMATION FOR SEQ ID NO: 136:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 26

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:136:

CTTGACTCTT CAAAAGAGAA AATTAC 26

(2) INFORMATION FOR SEQ ID NO: 137:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:137:

TCTCTATRTG CAYACGGAGC 20



(2) INFORMATION FOR SEQ ID NO: 138:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 138:

CCATACTGAT TGCCGCAAT 19

(2) INFORMATION FOR SEQ ID NO: 139:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:139:

CTTCGGTATC CTATTCCCGG 20

(2) INFORMATION FOR SEQ ID NO: 140:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:140:

GGATGCATCT CTGGTCATTG 20

(2) INFORMATION FOR SEQ ID NO: 141:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:141:

CTGGATGGTA TGGTGAGG 18

(2) INFORMATION FOR SEQ ID NO: 142:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:142:

GGAGGCCAAC AATTATTTC 20

(2) INFORMATION FOR SEQ ID NO: 143:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:143:

TAACAAACCG ATAATGGCGC 20

(2) INFORMATION FOR SEQ ID NO: 144:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:144:

CATCTTGTTA GAGGGATTGG 20

(2) INFORMATION FOR SEQ ID NO: 145:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:145:

CTCTTGAAAC TGGGAGACTT GA 22

(2) INFORMATION FOR SEQ ID NO: 146:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:146:

CCGTCAATTC MTTTRAGTTT 20

(2) INFORMATION FOR SEQ ID NO: 147:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:147:

GGTGGAGCTT CAATTGGAGA G 21

(2) INFORMATION FOR SEQ ID NO: 148:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:148:

GTGTAACCTA CTTTCATAAC ACCAG 25

(2) INFORMATION FOR SEQ ID NO: 149:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 149:

TTGGAAACGG TTAACGAA 20

(2) INFORMATION FOR SEQ ID NO: 150:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:150:

GAACCTTCCC ATCAAAAACA 20

(2) INFORMATION FOR SEQ ID NO: 151:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:151:

TCGCATCAAA CTGACAAACG 20

(2) INFORMATION FOR SEQ ID NO: 152:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:152:

GCAGGTACTC TATAAGTGCC 20

(2) INFORMATION FOR SEQ ID NO: 153:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:153:

GACATAAAAG CTAGGAATTT 20



(2) INFORMATION FOR SEQ ID NO: 154:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:154:

AAATCGGATT AACATTATCC 20

(2) INFORMATION FOR SEQ ID NO: 155:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:155:

CTAGTTTGGT AATATCTCCT 20

(2) INFORMATION FOR SEQ ID NO: 156:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:156:

TAATGCTATA TCTTATAGGG 20

(2) INFORMATION FOR SEQ ID NO: 157:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:157:

TAGATAAAGT TAAAACAAGC 20

(2) INFORMATION FOR SEQ ID NO: 158:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:158:

TAACTTACCG TGGACCCTTC 20

(2) INFORMATION FOR SEQ ID NO: 159:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:159:

ATGGCAGCAT CAGCTTGATA 20

(2) INFORMATION FOR SEQ ID NO: 160:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:160:

TTTCCAATAA CCACCCGTTT 20

(2) INFORMATION FOR SEQ ID NO: 161:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:161:

CTAGTGCATT TGTTATTCAA 20

(2) INFORMATION FOR SEQ ID NO: 162:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:162:

TGCATTGACA CCATAGTACT 20

(2) INFORMATION FOR SEQ ID NO: 163;

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:163:

ACGGCTATAT ACATTCAATT 20

(2) INFORMATION FOR SEQ ID NO: 164:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:164:

TCCATCGATA ATATACCTAA 20

(2) INFORMATION FOR SEQ ID NO: 165:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:165:

AACTGGAGGA AGGTGGGGAT 20

(2) INFORMATION FOR SEQ ID NO: 166:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:166:

AGGAGGTGAT CCAACCGCA 19

(2) INFORMATION FOR SEQ ID NO: 167:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 15

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:167:

CCACCTTGAC TATTT 15

(2) INFORMATION FOR SEQ ID NO: 168:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 15

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:168:

TTAATTAGGA GGTA 15

(2) INFORMATION FOR SEQ ID NO: 169:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 26

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:169:

CGTGGAGGCG ATCACACCGC AGACGT 26



(2) INFORMATION FOR SEQ ID NO: 170:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:170:

AGTGCGACGG GTGCACGTCG CGGACCT 27

(2) INFORMATION FOR SEQ ID NO: 171:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 35

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:171:

TTGGTTGCAC TTAAATTTT CCCATTAGTC CTATT 35

(2) INFORMATION FOR SEQ ID NO: 172:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 35

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:172:

CCTACTAACT TCTGTATGTC ATTGACAGTC CAGCT 35

(2) INFORMATION FOR SEQ ID NO: 173:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:173:

GARATNGGNN NNGGNAARGG NCA 23

(2) INFORMATION FOR SEQ ID NO: 176:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:176:

AGTTCTGCAG TACCGGATTT GC 22

(2) INFORMATION FOR SEQ ID NO: 177:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 17

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:177:

AGTTATCTAC ACGACGG 17

(2) INFORMATION FOR SEQ ID NO: 174:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 17

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:174:

AAYTGRTTYT TNGTRAA 17

(2) INFORMATION FOR SEQ ID NO: 175:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:175:

AAAATCGATG GTAAAGGTTG GC 22

(2) INFORMATION FOR SEQ ID NO: 178:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 17

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:178:

GGCGTACTAT TCACTCT 17

(2) INFORMATION FOR SEQ ID NO: 179:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:179:

ACCTACTCCC AACATCAGCC 20

(2) INFORMATION FOR SEQ ID NO: 180:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:180:

ATATAGATCT CACTACGCGC 20

(2) INFORMATION FOR SEQ ID NO: 181:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 17

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:181:

AGAGAATTAT GCAGTGC 17

(2) INFORMATION FOR SEQ ID NO: 182:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:182:

GACAGTTACC AATGCTTAAT CA 22

(2) INFORMATION FOR SEQ ID NO: 183:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:183:

CAGCTACATC GACTATGCGA 20

(2) INFORMATION FOR SEQ ID NO: 184:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:184:

GGGCTTCGGT GTACCTCAT 19

(2) INFORMATION FOR SEQ ID NO: 185:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal



(xi) SEQUENCE DESCRIPTION: SEQ ID NO:185:

AGCTCGTATG GCACCGGAAC 20

(2) INFORMATION FOR SEQ ID NO: 186:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:186:

TTGACCTCCC ACCCGACTTG 20

(2) INFORMATION FOR SEQ ID NO: 187:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:187:

CATCGCCGTC CCCGAATTTC AAA 23

(2) INFORMATION FOR SEQ ID NO: 188:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:188:

GATGCGGAAG ATACCGTGGC T 21

(2) INFORMATION FOR SEQ ID NO: 189:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

N: SEQ ID NO:189:  
 G CAGG 24

The first step in the process of creating a new product is to identify a market need. This is often done through market research, which can involve surveys, focus groups, and other methods of gathering information about consumer preferences and behaviors. Once a market need has been identified, the next step is to develop a concept for a product that addresses that need. This involves brainstorming ideas and creating a rough sketch of the product. The third step is to create a prototype, which is a physical model of the product that can be used to test its functionality and appeal. This is often done using 3D printing or other manufacturing techniques. Finally, the product is launched into the market, and its performance is monitored to ensure it meets the needs of the target audience.